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Abstract
Screening LCA has been used to gain further insight into the environmental performance of 
Gambrosol Trio,  a fluid used in Continuous Ambulatory  Peritoneal  Dialysis (CAPD) as a 
form of renal therapy. Gambrosol Trio (Trio) is produced and commercialised by Gambro 
AB, an international company with headquarters in Stockholm and historic roots in Lund, 
Sweden.  The  product's  distinctive  characteristic  is  its  three-in-one  compartment  bag  that 
allows a patient to use one of three standard glucose concentrations that form the basis of 
CAPD. This design has logistics and operational advantages compared to similar products 
packaged in single or dual compartment bags. This thesis was conducted as a first approach 
to  explore  whether  or  not  these  advantages  extend  to  the  product's  environmental 
performance from a cradle-to-grave perspective. The environmental burden of the product is 
explored from the production and processing of Trio's components, to the manufacturing of 
the  product  itself  to disposal of  generated waste from its use, including transportation  in 
between  these  stages  of  the  product  cycle.  The  assessment  was  made  based  on  the 
construction of the product map, the material requirements for its production and transport 
and  assigning  an  “Ecoscore”  based  on  the  Ecoindicator  99 method  as  presented  in  the 
Ecoindicator  Manual  for  Designers.  Results  indicate  the  majority  of  the  product's 
environmental burden is located at the production stage of its components with PVC based 
plastics taking the larger share.  A quick exploration of Polypropylene and  Polyethylene as 
substitutes did not indicate potential for improved environmental performance. Caution must 
be  exercised as the  effects  of  Phthalate  leaking in  land-fills  or  incomplete  combustion  in 
incinerators was not available as Ecoscores. Although this approach is based on Life Cycle 
Assessment, it does not have the validity that a full application of the method would provide; 
as such, results can only be used within the organisation as a tool to decide whether or not to 
continue efforts along this track and cannot be used to communicate claims to stakeholders 
or as the basis for definitive, company-wide decisions such as material substitution in their 
products.
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Executive Summary
Peritoneal Dialysis (PD) is a form of renal therapy for individuals that suffer loss of renal 
function.  A  catheter  is  permanently  attached  into  the  abdominal  wall  and  a  solution 
(peritoneal  dialysis  fluid  PDF)  is  infused  into  the  abdominal  cavity  where  the  peritoneal 
membrane is used as a filter  media to replace  the  filtration  function  of  the  kidneys.  The 
dialysis  solution  is  mainly  composed  of  glucose,  electrolytes  and  a  buffer  that  together 
simulate blood serum conditions to induce filtration through the peritoneum. There are three 
standard glucose concentrations in the market available to patients. The use of either one has 
different results as part of the therapy.
There are two types of PD techniques; Continuous Ambulatory Peritoneal Dialysis (CAPD) 
and Automated Peritoneal Dialysis (APD). CAPD is a self-administered manual procedure in 
which PDF is infused 4 times per day with each infusion lasting around 4 hours. APD works 
under the same principle but a machine controls the filtration overnight while the patient 
sleeps.
Gambro  AB is  one  of  the  leaders  in  renal  therapy  that  specialises  in  the  production  of 
hemodialysis and peritoneal dialysis products and systems. One of its latests developments is 
a CAPD product known as Gambrosol Trio. The product was developed with the aim of 
improving the function of PD and PDFs. The research conducted at Gambro resulted in a 
new  three-in-one  packaging  design  that  can  deliver  any  of  the  three  standard  glucose 
concentrations.
This design has obvious advantages from a logistics and operational point  of view since it 
simplifies transportation and storage both for the company and its customers. Apoteket AB 
is Gambro's  main  customer  in  Sweden and it  is  the  entity  responsible  to  deliver  dialysis 
supplies to patients undergoing renal therapy.
Gambro  AB's  facilities  in  Sweden  are  certified  in  ISO  14001  as  the  basis  for  their 
environmental management system. The record for the exact number of facilities certified 
world wide was not available at the time of writing; however, at least manufacturing facilities 
in  Europe  do  have  ISO  14001 certification.  The  organisation,  as  part  of  the  healthcare 
industry  as a whole,  has been  the  focus of  attention  of  stakeholders  that  have expressed 
concern over some of the materials used in the sector, specifically PolyVinylCholride (PVC) 
and one of the chemicals commonly used as an additive, phthalates. 
These two circumstances have prompted Gambro's Research and Development and Design 
Validation department to search for suitable approaches that can contribute to gain further 
insight into the product's environmental performance and that can also be used as systematic 
tools  to  contribute  in  the  decision  making  process,  especially  during  research  and 
development and redesign of the company's products and systems. This is seen as the next 
step to complement the use of ISO-14001 as the EMS for their routine operations.
This  thesis  explores  the  use of  a  Life  Cycle  Assessment  -based approach  to  explore  the 
product's performance with a cradle-to-grave perspective and using established environmental 
'ready to use' assessment methods. This approach, known as Screening LCA is proposed as 
an adequate way to begin the exploration and potential adoption of more detailed and robust 
exercises such as a full-scale Life Cycle Assessment.
Due to time and resource limitations, this thesis cannot provide conclusive evidence in the 
way that the execution of a full-scale LCA would. However, its aim is to assist Gambro AB in 
presenting the  company with a viable tool  to  continue their  environmental  commitments 
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while  providing  a  qualitative  assessment  of  the  product's  performance  that  pursues 
quantitative insight whenever data availability and usability make it possible.
The results are centered around the determination of an “EcoScore” for the product, taking 
into account the environmental impacts resulting from the production and processing of its 
main  components  (plastics  for  bags  and  other  items,  chemicals  for  the  solution  and 
cardboard  for  packaging),  the  assembly  of  the  product  itself,  the  transportation  from 
suppliers to manufacturing, to distribution and delivery to the patients; and finally disposal of 
waste generated during the use-phase.
An  integrated  assessment  tool,  “Ecoindicator  99,  Manual  for  Designers”  was  used  to 
determine  the  product's  EcoScore.  This  method  was  specifically  developed  for  internal 
discussion  in  organisations  interested  in  starting  to  evaluate  their  products  from  an 
environmental perspective but that may not be ready to commit to a large-scale undertaking 
on  the  level  of  a  full  LCA,  or  that  may  wish  to  find  areas  of  interest  to  focus  their 
environmental efforts.
The method was applied to Gambrosol Trio under a set of limitations and assumptions that 
were inevitable due to the scope and limitations of the thesis and the method itself. Crucial 
amongst them is the use of Region Skåne as the focus of the study, considering the product is 
sold throughout Europe and parts of Asia. Also important to note is that the method does 
not cover all the relevant processes involved in the production of Trio and some assumptions 
had  to  be  made  to  continue  the  analysis.  An  important  limitation  is  the  lack  of  an 
ecoindicator for a process equivalent to the actual mixing, filling and packaging of the fluid. A 
compromise was made by approximating with the use of energy consumption rates based on 
similar  processes  in  the  milk  industry  and  by  raising  those  requirements  by  an  order  of 
magnitude to reflect the higher need for hygiene and quality control in the medical sector. 
Likewise,  ecoscores  related  to  disposal  of  PVC  did  not  include  impacts  of  leaching  of 
Phtalates in landfills or incomplete combustion in incinerators. 
Results  show that  the  main  contributor  to  environmental  impacts  is  the  production  and 
processing of  the  product's  components  (plastics,  chemicals,  water  and packaging)  and of 
those, production of plastics (PVC) contributed the most. 
Two alternative materials were explored (Polypropylene and Polyethylene) as substitutes but 
were not able to reduce the product's Ecoscore (higher points mean higher impacts). It is 
important  to note  that  this  comparison was made on equal grounds in terms of  material 
requirements used for the plastic components. It was not established the extent to which the 
use of a different  material with different  properties (density in particular) would involve a 
change in the shape or weight of the plastic components. 
The advantages of Trio in terms of logistics of production and transport due to its three-in-
one design did not appear to translate into increased environmental performance. The main 
reason  was  the  observation  that  patients  under  CAPD  do  not  change  their  glucose 
concentration  on  a  contingency  basis.  Therefore,  they  do  not  necessarily  have  all  three 
standard concentrations available at all times which limits the effect of wasted product due to 
expiration or returns as was originally thought. 
Changes in prescription appear to be controlled by continuous and careful observation of 
each patients renal function and patients usually place orders for CAPD solutions with one or 
too  weeks  advance  notice.  Although  no  data  was  available  from  Apoteket  AB  on  their 
inventory status and supply protocols, it is reasonable to assume that they would track their 
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customer  demands  and  react  accordingly  when  placing  orders  with  the  CAPD  fluid 
manufacturers.
However,  there  were  some  indications  of  a  limited  amount  of  scrapping  taking  place  at 
Apoteket (even if it is not normally tracked). In the absence of concrete information, a quick 
calculation was made with a ten percent scrapping rate. Due to the nature of the ecoscoring 
method and the limitations in data available the product ecoscore was affected in a direct way. 
A given increase (10%) in manufacturing, transport and disposal because of wasted product 
led to an equal increase in the product's ecoscore (10% higher). 
IV
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1 Introduction
This  section  covers  the  general  background  and  reasons  that  prompted  this  thesis.  The 
problem formulation, goals and limitations are also included. The outline of the document is 
presented at the end of the section.
1.1 Background
Environmental awareness has been considerably increased in past decades. Seminal work  like 
that of Rachel Carson's  Silent Spring in the 1960s paved the way for a heightened level of 
concern among  the general public about our relationship to the environment. 
Following on her steps, countless natural scientists, engineers, politicians, artists, institutions, 
organisations and the public as a whole have contributed to reshape our society's view of the 
environment.  Organic farming, alternative energy technology and pollution  accords at the 
regional and international level are but some of the fruits of these efforts.
Little by little, stakeholders all around the world have been shifting their view of production 
and  consumption  systems  in  order  to  include  the  effects  of  those  systems  on  the 
environment,  moving  away  from  traditional  models  that  only  acknowledged  simple 
relationships  between  producers  and  consumers;  to  more  holistic  approaches  that  show 
society's connection to the environment and its role as a limited reservoir of raw materials 
and as a system that  provides numerous services but that  is also sensitive to,  and can be 
jeopardised by, inefficient production and  careless waste production and disposal practices.
A  shift  has  been  noticed:  beginning  with  reactive  approaches  such  as  tightening  of 
governmental regulation in the field of pollution emission and control, moving on to shifting 
attention  to  more  efficient  manufacturing  lines,  the  adoption  of  recycling  programs,  the 
development  and  widespread  adoption  of  environmental  management  systems  and  from 
there to preventive approaches such as design for the environment and sustainable business 
practices. All of these have marked the way for society's current interactions with our planet's 
natural systems.
Despite all these advances, society still demands a sometimes seemingly endless number of 
goods and services, some deemed more essential than others.  Some of us might find the 
switch from incandescent bulbs to fluorescent ones a rather painless transition in the quest of 
reduced energy consumption while others might shudder at the prospect of abandoning our 
cars and have them substituted with public transportation systems. Some may question the 
need to abandon them at all if we were to use an alternative energy source, thus reducing 
some of the negative impacts associated with their use. Is building lighter and more efficient 
vehicles,  perhaps  phasing  out  a  range  of  materials  and  substituting  them  with  others, 
reasonably  sufficient  efforts  when  dealing  with  personal  transportation's  negative 
environmental impacts?
These lines of thought resonate in most of society's production sectors, the health care sector 
being one of them. There are few other sectors that can be considered more essential than 
this one, a situation that can cause complications when trying to open a dialogue about the 
industry's environmental performance. It may not be a case of stakeholders and members of 
the  industry  not  genuinely  concerned  about  the  environment  but  simply  a  case  where  a 
function is considered so essential that other issues do not usually receive the same amount of 
attention.
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One of the pressure points for the medical sector is a heightened awareness of the materials 
used in plastic products such as gloves, blood and dialysis fluids bags, intravenous and feeding 
lines  and  similar  connecting  elements.  Polyvinyl  Chloride  (PVC)  has  been  the  focus  of 
attention due to concern as to the potential toxicity of one of one of the common plasticisers 
(Di(2-ethylhexyl)phthalate, DEHP) used in the production of this material. Although there is 
no definitive evidence of the effects of this compound on human health1, there is pressure on 
the sector to move away from either PVC containing DEHP or from PVC altogether2.
As a response to this pressure, a number of health centres around the world have initiated 
efforts to substitute PVC and/or DEHP for materials like silicon or polyurethane in the case 
of tubing;  ethylene vinyl acetate (EVA) for plastic bags and nitrile in the case of gloves. 
(HCWH, 2008)3. Blood bags are an exception due to the fact that phthalates act as a stabiliser 
for blood products and the use of PVC/DEHP is still common for this application4.
In the US, out of a total of 7,569 hospitals registered in 20055, a little over 100 (many of them 
children's hospitals) have started projects to substitute PVC/DEHP. In Europe, there cases 
reported where hospitals have been actively pursuing substitutes in Austria (18 health care 
centres),  Czech  Republic  (where  in  one  instance  the  targeted  product  was  IV  bags  for 
hemodialysis), Denmark and Sweden (with one major health centre each in Copenhagen and 
Stockholm, respectively).
In the case of southern Sweden, MA-Skåne, the entity in charge of material purchasing for 
the  region  has  purchasing  guidelines  that  recommend  the  use  of  PVC-free  alternatives 
whenever feasible and with the restriction that any substitutes should perform as well as the 
displaced products6. As of October, 2007 the efforts and results have been concentrated on 
the  following  items:  gloves,  injection  (syringes),  infusion  (insulin  pumps),  transfusion, 
anaesthesia (e.g., epidural sets), enteral nutrition (catheters and tubing), incontinence (drain 
lines) and office materials7.
Dialysis products in general and fluid bags in particular have not been addressed to the extent 
other items have because a switch of this nature represents a major overhaul for producers 
and distributors  as substitutes  may not  be  readily  available or  only  at  higher  costs8.  This 
punctuates the need for producers to have and use systematic tools that aid them in deciding 
how to better approach product design and redesign to cover issues like human health and 
environmental impacts.  
1 US Food and Drug Administration (2002). Public Health Notification: PVC Devices containing the plasticizer DEHP. Available online: 
http://www.fda.gov/cdrh/safety/dehp.html [September 01, 2008]
2 Health  Care  Without  Harm  (a2008).  Dioxins  and  Phtalates.  Available  online: 
http://www.noharm.org/europe/pvcDehp/dioxin-phthalates [September 01, 2008].
3 Health  Care  Without  Harm  (b2008).  PVC-free  alternatives.  Available  online: 
http://www.noharm.org/europe/pvcDehp/pvcFree [September 10, 2008]
4 Health  Care  Without  Harm  (2005).  Avoiding  PVC  Use  in  Hospitals.  Available  online:  http://www.noharm.org/europe 
[September 1, 2008].
5 US  Census  Bureau  (2005).  Available  online:  http://www.census.gov/Press-
Release/www/releases/archives/facts_for_features_special_editions/004491.html [September 10, 2008].
6 MA-Skåne  (a2008).  PVC-Free  Alternatives  for  Sustainable  Health  Care  in  Skåne.  Available  online: 
http://www.miljo.skane.se/eng/d/pd3.htm [September 10, 2008]
7 MA-Skåne (b2008). Products wihtouht PVC and PVC products without Phthalates. Available online: www.miljo.skane.se/eng/d/bilagor/PVC-
free_products.pdf  [September 10, 2008]
8 Medical  Device  Link  (2008).  PVC  and  Phthalates  in  Medical  Devices:  A  Never  Ending  Story.  Available  online: 
http://www.devicelink.com/mdt/archive/06/04/002.html [August 15, 2008].
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This thesis seeks to explore the efforts of Gambro AB, a member of this industrial sector, in 
addressing environmental  issues, similar to  the  ones  described above,  by using Life Cycle 
Assessment-based preventive approaches concerning one of their product systems.
Gambro AB, based in Stockholm, Sweden is one of the major global players in the area of 
renal  care.  It  currently  specialises  in  hemodialysis  products  and  systems  and  is  actively 
pursuing a bigger role in other renal therapy options such as peritoneal dialysis9.
Gambro AB has a long record of research and development and one of their most recently 
developed products, a peritoneal dialysis fluid  commercially known as Gambrosol Trio, is one 
of the available options for patients that experience severe renal deficiencies and that have 
not  been  able  to  receive  a  transplant.  Compared  to  hemodialysis,  peritoneal  dialysis  can 
provide a better  quality of life and due to its relative simplicity,  it frees the patients from 
constant  trips  to  hospitals  and  clinics  to  receive  treatment.  Furthermore,  the  design  of 
Gambrosol Trio appears to offer a superior performance in its critical role of substituting renal 
function when compared to traditional peritoneal dialysis fluids developed in the past.
Gambrosol  Trio  is  in  essence  a  glucose  solution  that  contains  a  number  of  electrolytes 
naturally  present  in  blood  serum.  The  fluid  is  instilled  into  a  patient's  abdominal  cavity 
through a catheter that is permanently attached to the abdomen, while instilled, it uses the 
peritoneal membrane's properties as a filtering medium to remove waste products and fluids 
from the body, in much the same way a healthy kidney would do.
Patients undergoing peritoneal dialysis may need one or more out of three standard glucose 
concentration fluids during the course of treatment. Some manufacturers produce this fluid in 
single concentration bags, thus requiring three separate products to cover a patient's needs. 
Others do so using dual concentration bags. Gambrosol Trio is currently the only fluid that is 
produced  in  a  three-in-one  concentration  bag,  meaning  a  patient  will  never  need  to  be 
supplied with a different type of bag if or when their prescription change.  
Gambrosol Trio's three-in-one compartment design was originally intended to increase the 
product's performance as part of a renal therapy system. However, the same characteristics 
that allow this product to perform its intended function also appear to be responsible for 
lessening the  environmental  impacts  associated with its  manufacture,  distribution  and use 
when compared to single and two-in-one compartment design fluids.
The details of this product's design, its relation to the environment, and how to systematically 
address its  environmental  performance using a preventive approach are the object  of this 
thesis and will be covered in the following chapters.
1.2 Problem formulation
The aim of this thesis is to critically explore Gambrosol Trio's environmental performance as 
a  peritoneal  dialysis  fluid  using  an  LCA-based  approach.  The  product's  three-in-one 
concentration design seems to have obvious advantages in reducing material intensity, storage 
and  transportation  requirements  when  compared  to  products  that  are  also  commercially 
available, that have the same function but a different design.
By  exploring  Gambrosol  Trio's  environmental  performance,  this  thesis  also  aims  to 
contribute to Gambro AB's current efforts to assess and if pertinent, to adopt a framework 
that  assists  in  the  decision  making process  by  including environmental  concerns  into  the 
organisation's research and development protocols.
9 Gambro AB (a2008). Available online: http://www.gambro.com [June 01, 2008].
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The  problem  formulation  can  be  summarised  in  the  following  primary  and  secondary 
research questions:
Are  there  any  qualitative  or  quantitative  indications  that  provide  further  insight  into  Gambrosol  Trio's  
environmental performance, in practice?
How can a framework based on Life Cycle Assessment can be used to initiate a systematic exploration of the  
product's  environmental  performance,  that  could be adopted as part  of  the  organisation's  current  decision-
making tools?
Answers to these questions will provide the means to reach the thesis objectives as stated in 
the following section.
1.3 Objectives
The main objective of the thesis is to propose an LCA-based framework that facilitates assessment of  
the environmental performance of product systems manufactured and commercialised by Gambro 
AB, using Gambrosol Trio as the focal point of the study.
A case will be made of how to use, in practice, such a framework in order to gain further insights into a  
product's  environmental  performance by  establishing key  components  in  the  manufacturing  and 
distribution chain and by exploring the way they operate so that potential areas of attention 
can be identified for further work on the topic.
1.4 Limitations
Gambro AB as an organisation and Gambrosol Trio as a product are both part of complex 
systems.  The study of both  systems in full is beyond the  scope of  this thesis due to the 
relatively short time period allocated to it as well as man-power constrains. Therefore, some 
limitations must be used to address the objectives stated above within a reasonable time and 
to a reasonable level of detail.
The selection of an appropriate framework for the assessment of environmental performance will be based on a 
literature  review of  current materials.  Emphasis  will  be placed on streamlined approaches  that reduce  the  
inherent complexity of this type of assessments when compared to stricter and more complex methods.
The proposed LCA-based framework will be regarded as a first step in terms of the effort 
within Gambro to develop a systematic  way to integrate environmental  performance as a 
criterion for the development of new products and/or redesign of existing ones. As such, it 
will  mainly  rely  on  qualitative  assessments;  whenever  possible,  quantitative  insight  will  be 
pursued.
A full LCA, that is, a quantification of the actual environmental performance of Gambrosol Trio throughout  
its life cycle is directly related to the availability of relevant data, its usability as well as the time allocated for  
research and it is not considered as within the scope of this exercise.
As for the product itself and to expedite access to key players in the system, the thesis will be contained to the  
Swedish  market  and qualitative  and quantitative  data  gathering  will  be  limited  to  region  Skåne,  where  
Gambro's Headquarters are located. Likewise, in the case of the manufacturing and distribution chain, the  
scope  is  limited  to  the  manufacturing  of  the  product  itself,  excluding  its  component  parts.  As  such,  the  
conclusions of this document may not be applicable to other parts of the peritoneal dialysis market.
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Other specific limitations that are related to the framework itself are addressed in detail in 
chapters 4 and 5.
1.5 Key facts and figures
Around 10% of the global population is estimated to suffer some form of kidney deficiency10.
About 1% of individuals afflicted with kidney disease will require renal replacement therapy11.
The numbers of those affected are estimated to steadily increase at an annual rate of 5 to 8 in 
developed countries%12
While historically the main causes of renal failure were trauma and non-specific inflammation, 
the causes are shifting to poorly treated diabetes and hypertension,  especially in developed 
countries13.
The total global market for renal therapy is estimated to be worth around USD 8.5 billion. Of 
this,  around 70% (~USD 5.97 billion)  corresponds to hemodialysis and 26% (~USD 2.25 
billion) corresponds to peritoneal dialysis14.
1.6 Thesis outline
Chapter 1. Introduction.
The first chapter will present background information required to understand the motivation 
behind this document. Problem definition, goals and limitations are also covered here.
Chapter 2. Methodology and Research Design.
This chapter provides an brief exposition of the methodology used throughout the thesis as 
well as the selected research strategy to address the research questions that  constitute the 
problem formulation.
Chapter 3. Kidney Function, Failure and Treatment options.
Contextual information is provided in this chapter with regards to the way the human kidneys 
work, the ways in which they can fail and the currently available treatment options. Emphasis 
is placed on filtration,  one of the kidneys main functions.  Likewise, out of the  two main 
treatment options (transplantation and dialysis) a more detailed description is provided in the 
case of dialysis. Within the category of dialysis, the chapter further explores peritoneal dialysis 
and  the  specific  product  around  which  the  document  revolves:  a  three-in-one  glucose 
concentration fluid  commercially known as Gambrosol Trio.
10 http://www.worldkidneyday.org/pages/facts.php   [June 20, 2008]
11 Glassock  R.J.,  Winearls  Christopher.  The Global  Burden  of Chronic  Kidney  Disease:  How valid  are  the estimates? 
Neprhon  Clinical  Practice  2008;110:c39-c47  .  Available  online: 
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000151244 [August 15, 2008].
12 El Nahas A.M., Bello A.K. (2005). Chronic kidney disease: the global challenge. Lancet. 9456 Vol. 365, 331-240 
13 See 10.
14 Gambro  (2005).  Annual  Report.  Available  online:  http://www.gambro.com/annualreport2007.htm [August  20, 
2008].
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This chapter,  together with chapter 4, provide the required information to understand the 
connection of the product design to the concept of environmental performance and sets the 
stage to begin the exploration of suitable methodologies that can be used to assess it. 
Chapter 4. Product Map.
This chapter will present the product map, describing its component parts and their origins, 
the product's manufacturing itself and its product's transportation routes  destination until it 
reaches the end-user.
Chapter 5. Life cycle-based approach to environmental performance.
Concepts  like  sustainable  enterprising,  corporation  evolution  and life  cycle  thinking,   are 
discussed under the lens of the research questions proposed in chapter 1. 
This chapter explores in further detail the main components of the proposed methodology, 
how it relates to, or has been adapted from, existing frameworks and tools and how it can be 
used to facilitate assessment of environmental performance and decision making within the 
organisation.
Chapter 6. Findings and Conclusions.
This chapter provides the results of the use of the proposed methodology to the targeted 
product system. It will present the findings of the qualitative assessment as well as quantitative 
insights that were gained during this exercise.
The main conclusions of the thesis are also presented in this chapter.
Chapter 7. Recommendations.
Recommendations based on the items covered in the previous chapter as well as observations 
made during the mapping of the product system will be provided here. They are indented to 
cover limitations to the results of this thesis and how to address them in future work and 
suggestions  on  how  to  make  use  of  LCA-based  tools  as  part  of  the  organisation's 
environmental management efforts.
Note: For those familiar with the concepts of renal function, failure and therapy and with 
Gambro  AB in  general,  it  is  recommended  to  proceed  to  chapters  6 for  a  view of  the 
proposed framework and its use and to  chapter  7 for  the  findings of  this  study and the 
concussions and recommendations.
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2 Methodology and research design
Given the characteristics of the problem defined in chapter 1, it was decided that this exercise 
would be approached using a case study oriented research strategy. Therefore, in order to 
answer the main research questions a research process was designed that would provide a 
reasonable amount of information to:
1. Create a map of Gambrosol Trio as part of a product system managed by Gambro.
2. Identify  areas of  interest  in the  product  map to focus on during subsequent 
work.
3. Select an appropriate general approach and a more specific method to explore 
the environmental performance of the product in the areas previously identified.
4. Collect  qualitative and whenever possible,  quantitative data to verify both the 
validity of the areas of interest previously identified, and 
5. To  use  the  selected  methodology  to  provide  answers  to  the  primary  and 
secondary research questions.
2.1 Data collection
Items  1 through  5 were  approached  through  a  combination  of  literature  reviews  and 
qualitative and quantitative data collection by means of interviews with key individuals inside 
and outside of Gambro AB. These reviews and interviews shaped the outline and results of 
this thesis as shown in fig. 2-1.
A number of experts within the organisation were selected to form a steering group that would 
provide guidance and extended critical discussion conducted through open conversations in 
order to gain the required level of understanding to map the product system.
The participants in this steering group were:
1. Anders  Wieslander.  Senior  Researcher.  Member  of  the  original  research  group 
responsible for the development of Gambrosol Trio. Steering group leader.
2. Malin Isaacson. Sales Manager. Peritoneal Dialysis (Product System Mapping)
3. Theodor  Sandström.  Director  of  R&D.  Materials  and  Chemistry  Development 
(Product System Mapping).
4. Barbara  Musi.  Senior  Researcher.  Toxicology  and  Biocompatibility  / 
Environmental Management (Background on materials and development protocols 
used within the organisation. Insight into current status of Gambro's environmental 
management system). 
Three extended sessions with the steering group were allocated during the thesis period. One 
at the beginning to formulate the problem and goal followed by a midterm one to review the 
methodology and course of action and finally one prior to submission to discuss findings and 
conclusions.
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Additional  interviews were  conducted  to  collect  additional  qualitative and where  possible, 
quantitative data. The list of interviewees and their relevant role are presented as follows.
1. Mikael  Redin.  Logistics.  Distribution  Centre  (quantitative  data  on  the  product 
characteristics: weight, manufacturing points, shipment destinations).
2. Tom Lindhal. Product delivery. Responsible for the delivery of dialysis supplies from 
Apoteket to patients in Malmö (quantitative data on delivery logistics collected during 
interview and observation of a full delivery day).
3. Lena  Krutzen.  Head  of  Peritoneal  Dialysis  unit.  Universitetssjukhuset  i  Lund 
(quantitative  data  on  number  f  patients  under  PD  treatment,  qualitative  data  on 
treatment option trends)
4. Katalin Kiss. Pharmacist. Apoteket, Universitetssjukhuset i Lund  (qualitative data on 
product delivery to end-users and storage practices at Apoteket).
5. Lena Kempf. Head Pharmacist, dialysis unit. Apoteket, Universitetssjukhuset i Malmö 
(qualitative data on product delivery to end-users and storage practices at Apoteket). 
Once the  product  map was established,  a literature review was conducted to identify and 
select  a suitable framework capable of assessing the product's  environmental  performance 
and becoming a complementary tool in the organisation's decision-making process.
The key factors for the selection of an LCA-based approach as a suitable framework for this 
excercise were:
• Holistic nature. Early on, during discussions with the steering group and while 
constructing the product map, it became clear that even though the exercise was 
prompted by a scientific and technological innovation (the three-in-one design 
of Gambrosol Trio), the effects of this innovation would resonate beyond the 
boundaries of the organisation itself. Therefore, it was decided that an approach 
able to go beyond technological solutions and that could frame the product as 
but a “part of a whole” would be preferable. 
• Conducive to objective results. One of the first points of discussion with the 
steering  group  was  the  need  to  create  a  systematic  approach  to  include 
environmental  issues  as  one  of  the  core  components  in  the  organisation's 
decision making process, beyond routine operations. In order to do that,  the 
selected framework  would have to be able to offer some measure of objectivity 
in its results.
• Good ratio of comprehensiveness/expediency. The potential to streamline the 
frameworks  was  considered  as  a  positive  factor  due  to  the  time-related 
constrains of the study.
Once  having  a  selected  framework,  literature  review  continued  to  identify  how  this 
framework  could  be  adapted  to  assess  the  product's  environmental  performance  while 
maintaining the same three criteria stated above.
The main components of the selected framework were applied to the product system itself to 
gain  qualitative  insight  into  its  environmental  performance.  Where  data  was  available  or 
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usable,  an  effort  was  made  to  complement  this  with  quantitative  insights.  The  resulting 
findings, conclusions and recommendations  are contained in chapters 6 and 7.
2.2 Validity, reliability and objectivity
The  validity  and  reliability  of  the  findings  presented  in  this  thesis  are  dependant  on  the 
comprehensiveness  of  the  literature  review and the  accuracy  and adequate  assessment  of 
qualitative and quantitative collected data.
An effort was made to review and critically compare the broad approaches described above 
and the resulting framework.  These items were presented to the steering group and their 
function, implications and limitations were subject of discussion to verify their validity as a 
means to answer the primary and secondary research questions.
The  objectivity  of  the  results  is  liable  to  be  compromised  due to  the  limited amount  of 
quantitative data that was collected, either due to it being not available, usable or because of 
its sensitive nature.  
It is acknowledged that data collection during open conversations and unstructured interviews 
risks the interviewer to ask leading questions and thus receive skewed qualitative data that may 
include untested and/or hard to verify observations from the interviewees.
The author made an effort to maintain a critical approach to the results of all interviews and 
discussions, more so in the case of those with the steering group. Although an effort was 
made by  all participants  to remain critical during discussions there  is  always the  risk of  a 
certain degree of bias to enter the conversation. To counteract this, an effort was made to 
contrast the information obtained in this manner to the established general approach and 
framework that resulted from the literature review.
As for the application of the framework itself, it must be observed that an strict application 
of Life Cycle Assessment was considered to be outside the scope of this study. Therefore, the 
results presented herein do not possess the validity that a full LCA would have. Chapter 6 
states in detail the differences from the standard LCA method that were used throughout this 
exercise. 
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Figure 2-1Research Action Plan & Document Outline
……..
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3 Renal function, renal failure and treatment options
The  section  begins  with  a  general  introduction  to  renal  function,  renal  failure,  its 
consequences  and  treatment  options.  This  is  followed  by  a  more  detailed  description  of 
Peritoneal Dialysis (PD), one of the currently available treatment options for this condition, 
as well as some of the systems and products that deliver it.
Although the  purpose  of  this  section  is  not  to  provide  and exhaustive  treatment  of  the 
mechanisms and processes that take place in our kidneys, the information presented herein to 
describe their function will hopefully provide sufficient context as to their importance as a 
part of a bigger system. Likewise, a description of the ways this sub-system may fail and the 
therapy options that have been developed to provide a functional substitute are meant to give 
the  context  required  to  understand  the  connection  of  this  topic  to  environmental 
performance through the lens of life cycle thinking and environmental management (chapters 
5 and 6).
The descriptions mentioned above provide the basic reasons for conducting this exercise in 
the context of environmental performance and life cycle thinking. An introduction to these 
two concepts will also be provided. In a similar manner, the problem definition, purpose and 
limitations are also addressed in this section.
3.1 Renal function basics
One of the functions commonly associated with kidneys is that of waste removal. In general 
terms, kidneys are the organs in charge of removing waste products from our blood streams 
producing urine as the vehicle for their final disposal.
Their function, humble in appearance when compared to other, more illustrious components 
of  the  human  anatomy  is  nevertheless  considered  as  one  of  the  key  developments  that 
allowed our distant ancestors to take the jump out of our planet's oceans to thrive in dry 
environments where the extremely risky proposition of an ever changing environment was 
minimised by the ability to maintain their internal environment in a more or less constant 
state15.
A big part of the ability to regulate our internal environment is the domain of the kidneys' 
filtering functions. Plasma (blood  sans its suspended elements) is continuously processed in 
complex substructures called nephrones, microscopic repeating units into which the kidney is 
divided. (see Fig. 3-1 for an illustration of the working principles of these substructures16). 
These structures and their corresponding components are in charge of the constant filtering 
and absorption steps that allow our bodies to clean our blood streams while retaining useful 
substances  thus helping  to maintain a stable  internal  state.  Under  normal  conditions,  the 
kidneys of an average healthy adult will filter the equivalent of up to 15017 litres of fluid each 
day to produce about 1.5 litres of urine18,19.
15 Sullivan, Lawrence P. (2002).
16 A human kidney is essentially a collection of about one to one and a half million nephrons. Although not clearly visible in Fig. 1, blood 
vessels surround the whole structure (dashed line) and water and solutes move back and forth through the nephron's wall. In other words, 
nephrons operate in a  way similar to that a shell and tube, concurrent heat exchanger would do, except that “mass” is exchanged instead.  
One of the core drivers for the mass transfer that takes place is the difference in tonicity of the plasma-blood solution in both structures. 
Hypertonic conditions outside of the nephrons at number 3 (a region permeable to water but semi-impermeable to salts) result in water 
moving out of the nephron and into the blood vessel. Likewise, hypotonic conditions in the area marked as 4 (impermeable to water but 
permeable to salts) result in the movement of solutes (e.g., sodium) from nephron in the same direction. 
17 This number corresponds to all the absorption and reabsorbtion 'loops' required to clean the bloodstream of an average adult. 
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Figure 3-2: Filtration in the kidney's nephrons.
In addition to the intricate hydraulic arrangements that make it possible for kidneys to clean 
our blood, they are also responsible for regulating blood pressure by producing an enzyme 
that is part of a complex system (see Fig 3-2.) involving both liver an lungs. The end result is 
the production of another enzyme that cause salt and water retention in the kidneys, thus 
increasing blood pressure20.
Figure 3-3: Blood pressure control in the kidneys.
The kidneys are also part  of  another  complex system that  regulates calcium levels in our 
bodies  resulting  in  bone  mineralisation.  In  another  instance  of  systematic  cooperation,  a 
18 Ginsburg,  J.M., Borke,  J.  L. (1999).  Essentials  of  Human Physiology.  Ch. 7. Renal  Physiology.  Ed.  By Thomas M. 
Nosek. Available online: http://www.lib.mcg.edu/edu/eshuphysio/program/default.htm [August 25, 2008]
19 A  comprehensive,  yet  easy  to  understand  walkthrough  of  kidney's  filtering  function  can  be  found  at 
http://pcwww.liv.ac.uk/~petesmif/petesmif/why%20do%20we%20need%20kidneys/index.htm#3 
20 National Library of Medicine. 2008. The Renin-Angiotensin System. Available online: http://www.nlm.nih.gov/cgi/
mesh/2008/MB_cgi?mode=&term=Renin-Angiotensin+System [2008, August 10]
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precursor  of  Vitamin  D  is  modified  in  the  skin  by  exposure  to  sunlight.  The  resulting 
molecule is then further modified in the liver. The kidney then makes the final modification 
and produces the active form of Vitamin D. This final step is also applicable to Vitamin D 
ingested as part of our diets as it also requires modification by the kidneys to become active. 
A  Vitamin  D  deficiency  results  in  bone  deformities  commonly  known  as  rickets.  While 
adequate exposure to sunlight and a balanced diet are enough to prevent the condition this is 
dependent on the kidneys condition as they are ultimately in control of the production of the 
vitamin's active form21.
Finally, the kidneys are also major contributors in the oxygen transport system in our bodies 
This is accomplished by the production of erythropoietin (EPO), a hormone that stimulates 
the  red blood cell  production  in our bone  marrow22.  Whenever low levels of oxygen are 
detected in the kidneys, they release EPO which is a detonator for the conversion of 'multi-
purpose' stem cells that are located in bone cavities. Contact with EPO results in these stem 
cells developing into red blood cells23.
This last feature has received some attention in media and sports circles in the past 30 years 
due to the practice of some athletes of using a synthetic form of EPO to stimulate red blood 
cell production thus enhancing oxygen transport potential and consequently improving their 
endurance. EPO was banned by the International Olympic Committee in the early 1990s and 
the first comprehensive detection test was introduced in the 2000 Summer Olympic Games 
in Sidney, Australia24.
3.2 Renal failure: Description and relevance
Renal failure is  said to occur when the  kidneys lose their  ability  to  perform their  natural 
functions. This means the kidneys may no longer be able to filter waste products out of the 
blood stream, to keep the appropriate levels of electrolytes in our bodies, to control blood 
pressure and to stimulate production of red blood cells as needed25
Renal failure is classified  into two categories: Acute Renal Failure (ARF) and Chronic Kidney 
Disease (CKD).  Both  types  of  failure represent  a loss of  renal  function  and vary in how 
quickly this function is lost. CKD involves reduced renal function during a time period of 
three months or longer while ARF stands for a rapid loss occurring in an interval of days or 
weeks26.
In general terms, AKF develops when blood flow to the kidneys is abnormal. This may come 
as a  result  of  blood  loss,  severe  dehydration  or  obstructions  in  the  renal  artery  or  vein. 
21 Bowen, R.A., et al. (2006). Patophysiology of the endocrine system. Available online: http://www.vivo.colostate.edu/
hbooks/pathphys/endocrine/otherendo/vitamind.html [August 05, 2008]
22 Medicinenet  (a2008).  Erythropoeitin  (EPO)  and  EPO  test.  Available  online: 
http://www.medicinenet.com/erythropoietin/article.htm [July 25, 2008]
    http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/B/Blood.html#formation   ][September 10, 2008]
23 A number  of triggers  such as EPO are responsible  for the creation of white cells  (part of the immune system and 
platelets (partly responsible for blood coagulation).
24 World  Anti-doping  Agency  (2008).  Available  online:  http://www.wada-ama.org/en/dynamic.ch2?
pageCategory.id=527 [June 15, 2008]
25 Medicinenet (b2008) Kidney Failure. Available at  http://www.medicinenet.com/kidney_failure/article.htm [May 
04, 2008]
26 U.S.  National  Kidney  Fundation  (2008).  How  your  kidneys  work.  Available  online: 
http://www.kidney.org/kidneydisease/howkidneyswrk.cfm#what [May 15, 2008].
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Another  cause  of  AKF is  direct  injury  to  the  kidneys.  Examples  are  damage  caused  by 
inflammation in the event of severe infection27, intake of medications that are toxic to the 
kidneys,  overload  of  the  kidney's  filtering  capacity  as  a  result  of  crushing  injuries  that 
breakdown muscle tissue28. Finally, obstructions that alter urine flow downstream from the 
kidneys may also result in renal failure as pressure increases while the kidneys continue their 
filtering  function  until  they  eventually  shut  down.  Kidney  stones,  tumors  and  prosthate 
cancer are amongst the responsible causal agents of these obstructions29.
Even  though  CKD  is  also  triggered  by  abnormal  blood  flow,  in  this  case  this  is  most 
commonly caused by poorly treated pre-existing conditions such as diabetes, chronic high 
blood  pressure,  or  chronic  gromerulonephritis  –an  inflammation  of  the  kidney's  filtering 
subsystems (illustrated in Fig. 3.1). 
According to the International Society of Nephrology30 and the International Federation of 
Kidney Foundations31 through their  joint  project  “World Kidney Day”, about 500 million 
individuals world-wide are affected with some form of renal failure. In Europe, the number 
of cases is estimated to be around 4.5 million. Furthermore, mortality rates amongst those 
suffering renal failure is estimated to be around 20%32.  Other estimations have placed the 
incidence of CKD in Taiwan at around 12% of the  country's  population whereas that  of 
Australia, Japan and Europe ranges from 6 to 11%33.
Loss of  renal  function  in  individuals suffering from CKD can reach a point  where  renal 
replacement  therapy  is  required  (see  the  following  section  for  a  description  of  therapy 
options).  This  is  referred  to  as end  stage  renal  disease  (ESRD).  Estimates  for  developed 
countries show that the number of ESRD cases is expected to increase at an annual rate of 
around 5 to 8%. The estimates for developing countries  anticipate  the  number  of  ESRD 
cases to triple from 99 million in 2005 to around 286 million in 202534.
In monetary terms, around USD 28 billion35 are devoted to ESRD  to cover about 26 million 
cases in the U.S.36 while in Europe this condition takes up to 2% of the health care budget for 
the 4.5 million currently receiving treatment.
It is important to note that some studies have provided indication that not all CKD cases 
will necessarily reach a stage where renal replacement  therapy is required1. In Europe for 
example,  only  around 1% of  individuals with CKD will see a loss  of  renal  function  that 
requires replacement therapy.
27 Only  in the case  of sepsis,  a general  infection that causes  an overreaction of the immune system that is  ultimately 
responsible for inflammation and shut down of the kidneys.
28 In this instance, the products of muscle fiber breakdown are carried in the bloodstream and may eventually 'clog' the 
kidney's filtering system.
29 See 14.
30 http://www.nature.com/isn/index.html   [June 20, 2008]
31 http://www.ifkf.net/   [June 20, 2008]
32 European  Renal  Genome  Project  (2008).  Available  at: 
http://www.euregene.org/euregene/pages/public_science_info_e.htm [June 20, 2008]
33 El Nahas A.M., Bello A.K. (2005). Chronic kidney disease: the global challenge. Lancet. 9456 Vol. 365, 331-240 
34 Ibid
35 Ibid
36 National Kidney Foundation (2008).Available online:  http://www.kidney.org/kidneydisease/ckd/index.cfm [June 
20, 2008).
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3.3 Treatment options
Regardless of the nature of the condition, i.e., AKF or CKD, part of the treatment consists 
of renal function replacement, either by undergoing kidney transplantation or by means of a 
procedure  known as dialysis.  Two types  of  dialysis  are  available:  hemodialysis  (HD)  – in 
which the blood of the patient is pumped through an external filtering media and returned to 
the body; and peritoneal dialysis (PD) in which a solution of minerals and glucose is instilled 
into  the  peritoneal  cavity  through  a  catheter  in  in  order  to  use  the  patient's  peritoneal 
membrane as the filtering media. This membrane replaces the filtering function illustrated in 
Fig. 3-1.
Hemodialysis  as  a  renal  replacement  therapy  begun  development  in  the  late  nineteenth 
century  but it would take almost fifty years to see the first recorded recovery of a patient 
suffering from ARF in 1943. In a similar way, the principles behind peritoneal dialysis were 
first observed in the late eighteenth century but reliable therapy methods would have to wait 
until the mid twentieth century when catheters had been developed to prevent infection and 
to reduce the need of repeated incisions each time the treatment was required37.
Hemodialysis is most commonly carried out at health centres (although recent developments 
have made possible to  receive treatment  at home) that  have the  required equipment  and 
usually takes place in single 4 to 6 hour sessions, three times per week. 
Peritoneal dialysis requires a surgical procedure to insert a catheter through which a glucose 
solution is pumped into the patient's  abdominal cavity.  Once the procedure is completed, 
equipment requirements are considerably lower than hemodialysis and the treatment can be 
conducted at home. 
3.4 Hemodialysis & peritoneal dialysis
Although the use of peritoneal dialysis as a treatment is considerably smaller when compared 
to hemodialysis (see section 3.4)  , a trend has been observed for a slow but sustained switch 
from hemodialysis to peritoneal dialysis as a first treatment option38. 
There are two main reasons for this shift. The first is that continuous use of hemodialysis can 
have a significant negative impact on patients' vascular access (the connection point into the 
circulatory system used to perform hemodialysis, similar in principle, to the catheter used in 
peritoneal  dialysis)  during  the  course  of  the  treatment   that  leads  to  a  reduction  in  the 
effectiveness of hemodialysis as a renal replacement therapy. Additionally, hemodialysis has 
been observed to cause a reduction  in the  production  of  urine (urine is still  produced in 
patients suffering from loss of renal function) which in turn has been observed to negatively 
affect patients quality of life and survival rates39.
Loss of vascular access may be caused by complications such as inflammation of the access 
point, infiltration and reduced flow amongst others. Complications associated with vascular 
access have been estimated to account for up to 20% of hospital admissions among patients 
with advanced degrees of chronic kidney malfunction.
37 Fresenius  (2008).  History  of  Peritoneal  Dialysis.  Available  online:  http://www.fmc-
ag.com/internet/fmc/fmcag/neu/fmcpub.nsf/Content/Dialysis_Compact_2005_0 [June 15, 2008]
38 Personal communication. Lena Krutzen. Head nurse, dialysis unit at Universitetssjukhuset i Lund 
39 US  National  Kidney  Foundation  (2006).  Clinical  Practice  Guidelines  and  Clinical  Practice  Recommendations. 
Hemodialysis  adequacy,  peritoneal  dialysis  adequacy,  vascular  access.  Available  online: 
http://www.kidney.org/Professionals/kdoqi/guideline_upHD_PD_VA/index.htm [August 25, 2008]
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To understand the cause for the loss of urine production due to hemodialysis it is important 
to remember  that  blood filtration,  and therefore  urine  production  is dependent  of  blood 
pressure levels (as illustrated in fig. 3-1). In simple terms, when undergoing hemodialysis, large 
volumes  of  blood  are  removed  from  the  body,  creating  a  pressure  drop  that  eventually 
reduces the amount of urine produced.
3.5 Peritoneal Dialysis
There  are two different  treatment  options  within PD: Continuous Ambulatory  Peritoneal 
Dialysis (CAPD) in which short dialysis sessions (each lasting 4 to 5 hours) are conducted 4 
times per day (see Fig. 3.3) and Automated Peritoneal Dialysis (APD) in which a machine, 
commonly known as a dialyser, that automatically pumps the dialysis fluid in and out while 
the patient sleeps.
Figure 3-4: Continuous Ambulatory Peritoneal Dialysis (CAPD) basics.
Patients using PD as a renal function replacement therapy require a number of items as part 
of the treatment. These items are:
• Dialysis fluid
• Catheter
• Connecting lines (fluid bag to catheter and catheter to drain bag)Drain bag
• Disposable aseptic towels
• Catheter adapter
• Dialyser (for Automated Peritoneal Dialysis only).
As  can  be  seen  from the  list  above,  due to  the  relative  simplicity  of  the  PD technique, 
material  requirements  are  limited,  a  fact  that  greatly  facilitates  the  ability  of  patients  to 
conduct their treatment on their own. Furthermore, dialysis fluids have been developed to 
reduce discomfort  during the dwell phase so that  patients are able to continue their  daily 
routines as close to normal as possible40. 
While the catheter is a very important component of PD treatment (enabling a permanent 
connection for the fluid exchange process, thus reducing stress by repeated incisions to the 
abdominal cavity) the core of the treatment resides in the PD fluid. Table 2 shows the typical 
40 Personal communication. Anders Wieslander. Gambro Lundia AB.
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composition of a standard PD fluid unit as well as their function. These PD fluid units or 
bags hold 2 liters of fluid when used in CAPD (one per exchange) and 5 liters when used in 
APD (where two bags of 5 L each are used overnight). 
Drain bags and connecting  lines are supplied to patients  along and they  hold the dialysis 
product, known as dialysate. Disposable, aseptic towels are often supplied to patients in order 
to help with cleaning of the area surrounding the catheter. Hygiene is always stressed as an 
important factor for the continued performance of PD treatment as lack of proper care may 
result in infection and complications for the PD patient41.
Finally, catheter adapters are sometimes supplied so that patients may use PD fluids produced 
by different manufacturers that posses incompatible connections to the catheter.
Table 1: CAPD main components and their function
Component Function
Electrolytes (Sodium, Chloride, 
Calcium and Magnesium).
To create an isotonic (equal 
concentrations of solutes) 
environment on both sides of the 
peritoneum to match those of normal 
plasma.
Buffers (Lactate). To regulate acidity in the 
bloodstream.
Glucose. Osmotic agent. Regulates diffusion 
through the peritoneum (higher 
concentrations stimulate removal of 
liquids from the body).
Perhaps the most distinctive feature of the dialysis fluid is its glucose concentration. Glucose 
concentration affects the amount of water that is drained from the body during any given 
exchange.  With  greater  concentrations  of  glucose,  a  higher  amount  of  water  is  diffused 
through the peritoneal membrane, leaving the body to be collected in the drain bag. Although 
concentration options vary depending on the manufacturer of the PD fluid, there are always 
three  of  them  available  to  patients.  They  range  from  1.5  to  5%  with  the  medium 
concentration around 2.3%
Each PD patient is assessed by their physician and prescribed the concentration that better 
suits  their  treatment  needs.  For  example,  if  a  patient  has  been  retaining  liquids  as  a 
consequence of either illness or the treatment itself, a higher concentration will be preferred 
in order to stimulate diffusion of water through the peritoneum and eventually into the drain 
bag42.
PD fluids are commercially available in one of three presentations, either as single, double or 
triple concentration bags. Single concentration designs are bags with 2 liters of fluid in either 
low, medium of high glucose concentration. 
Double concentration bags keep glucose at low pH (glucose naturally degrades at close to 
neutral  pH)  in  one  compartment  while  the  second  compartment  rises  the  fluid's  pH 
41 Personal communication. Lena Krutzen. Dialysis Unit. Universitetssjukhuset i Lund.
42 Ibidem.
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immediately before infusion into the peritoneum. A line takes fluid from each of the two 
pouches and takes it to a valve with preset positions that is intended to simplify the dialysis 
procedure by removing clamps and pins as is the case in the three-in-one design.
Finally, three-in-one designs consist of a three compartment bag that delivers any of the three 
glucose concentrations depending on the number of compartments used. Two compartments 
contain  concentrated  glucose  at  low pH.  By  breaking  the  pins  in  one  or  both  of  these 
compartments the bag reaches either of the three glucose concentrations required. (see fig. 3-
4 for an illustration of each of these designs).
Figure 3-5: Schematic of commercially available PD fluids packaging design
3.6 Gambro AB
Gambro  AB  is  an  international  company  headquartered  in  Lund,  Sweden  with  market 
presence in 40 countries. The company is specialised in medical technology, developing and 
delivering products, therapies and services for hemodialysis, peritoneal dialysis, renal intensive 
care, hepatic care and water purification.
Up until 2006, the entity known today as Gambro AB was part of a publicly traded company 
that had three main business areas: Gambro Renal Products (GRP), Gambro Healthcare and 
Blood Component Technology (BCT). In July 2006, Gambro was acquired by Investor AB43, 
an industrial holding group based in Sweden. Gambro was subsequently removed from the 
Stockholm Stock Exchange and divested itself of Gambro Healthcare and BCT. 
According to the last full Annual Report published by Gambro in 200544 before the change of 
ownership that occurred the following year, the total renal products market was estimated to 
be worth USD 8.5 billion, out of which Gambro had a share of 17%. The two other main 
players were U.S. Based Baxter and Fresenius Medical Care with 23 and 29% market share 
respectively.
With regards to hemodialysis, the total market was estimated to be worth around USD 6 
billion out of which Gambro had the second largest market share (20%), behind Fresenius 
Medical Care (34%) and well ahead of Baxter (7%) with the remaining 39% distributed among 
other players.
In the  peritoneal  dialysis category,  the  total  market  was estimated to be worth  USD 2.25 
billion or just over 26% of the total renal market. Of this, Gambro held a share of 2% with 
Baxter well ahead (69%) and Fresenius trailing behind (19%). In 2008, the market share of 
43 www.investorab.com   
44 Gambro  (2005).  Annual  Report.  Available  online:  http://www.gambro.com/annualreport2007.htm [August  20, 
2008].
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Gambro  in  the  peritoneal  dialysis  sector  is  estimated  to  be  around  30% in  the  Nordic 
countries with no data available for the total market45.
The company is currently using a certified environmental management system based on ISO 
14001 for its routine operations. At the time of writing restructuring was taking place with the 
addition of a new environmental manager to coordinate environmental affairs.The facilities in 
Sweden  are  all  ISO  14001  certified  but  the  extent  of  certification  world-wide  was  not 
available. It  was indicated that at least all manufacturing facilities in Europe have received 
certification. Furthermore, as part of the work in the Research and Development and Design 
Validation  department  a  new  project  was  been  started  to  explore  the  potential  of 
integratation of ISO-1400 EMS criteria into project development operations protocols46. 
3.7 Gambrosol Trio
Gambrosol Trio is one of the PD fluids currently manufactured by Gambro AB and available 
in  the  European  and  Asian  markets.  A  distinctive  feature  of  this  product  is  the  three-
compartment design that allows a patient to receive any of the three standard concentrations 
of glucose in the dialysis fluid. The packaging design of Gambrosol Trio (see fig. 3-5) allows 
the patient to configure the use of the product for one of three concentrations in a single 
pack: using only large compartment  “C” the user receives a solution of glucose 1.5%. By 
combining “B” and “C” (by breaking a seal connecting them, see orange tips in fig.1) the user 
receives a solution of glucose 2.5%. By combining all three compartments, the user receives a 
solution of glucose 3.9%.
Figure 3-6: Three-in-one bag design of  
Gambrosol Trio
Conventional PD fluids are produced in single concentration bags while some manufacturers 
have opted for dual concentration designs. Fig. 3-6 shows the two-in-one design currently 
used by Fresenius Medical Care and Gambro's Gambrosol 10L.
45 Personal communication. Malin Isacsson. PD Sales Manager, Gambro AB.
46 Personal communication. Barbara Musi.  Senior Scientist, Research and Development and Design Validation, Gambro 
AB.
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Figure 3-7: Dual and single concentration PD fluid bags
Sources: Fresenius Medical Care (2008), Gambro AB (2008). 
Gambrosol Trio's three-in-one design was developed to address a problem with PD fluids 
first identified by researchers at Gambro's cell toxicology laboratory in Lund, Sweden. In a 
series of studies that date back to the early 1990s47, it was discovered that PD fluids had a 
toxic  effect  on  cultured  cells.  The  research  led  to  the  identification  of  so-called  Glucose  
Degradation Products (GDPs), a group of highly reactive aldehyde compounds that are formed 
when glucose is exposed to high temperatures, especially during sterilisation but also during 
storage if temperatures reach 25°C. The same research identified GDP formation increasing 
in strong relation to higher temperatures with two-fold increases at 40°C and three-fold at 
60°C.
The  chemicals  collectively  known as GDPs include fructose,  acetaldehyde,  formaldehyde, 
methylglycoxal,  glyoxal,  3-Deoxyglucosone  (3-DG)  and  3,4-dideoxyglucosone-3-ene  (3,4-
DGE).  Of  these,  3-4  DGE  has  been  identifiedas  one  of  the  most  biologically  active48 
compounds in PD fluids exposed to high temperatures as mentioned in the paragraph above. 
GDPs are a cause of concern in PD therapy because these molecules have been observed, 
both  in  in-vitro  and  in-vivo  studies,  to  contribute  to  the  deterioration  of  the  peritoneal 
membrane in patients  undergoing CAPD treatment49.  Some of the effects of  GDPs have 
been observed to manifest as inflow pain and reduced filtration rates in patients exposed to 
these chemicals50.
In general terms, GDPs are present in all PD fluids as a consequence of high temperature 
sterilisation  but  the  effects  of  temperature  during  transportation  and  storage  can  be 
controlled by maintaining glucose in a concentrated form (in compartments A and B in the 
case of Gambrosol Trio) at low pH levels (~3.1) and low temperatures (~20°C) right until the 
47 Gambro (c2008).  Glucose  Degradation Products  (GDPs).  An underestimated  factor  in peritoneal  dialysis.  Available 
online:  http://www.gambro.com/int/Treatment-offerings/Peritoneal-Dialysis/Products/Peritoneal-Dialysis-
Fluids/ [June 10, 2008]
48 Musi B. (2003). Biocompatibility of Peritoneal Dialysis Fluids: Impact of glucose degradation products, pH and buffer 
choice  on peritoneal  transport  and morphology  in the rat.  Doctoral  Dissertation.  p. 17.  Faculty  of Medicine,  Lund 
University.
49 Idem.
50 Jorrës A. (2003). Glucose Degradation Products in Peritoneal Dialysis: from bench to bedside. Available online: http://
content.karger.com/ProdukteDB/produkte.asp?Doi=70993 [September 10, 2008].
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moment  where  it  needs  to  be  used  when  pH  reaches  less  acidic  levels  (~6.6)  by  the 
combination  of  any  two  concentration  compartments  and  temperature  is  increased  by 
heating up the bag until it approaches normal body temperature (~35°C)51.
While Gambrosol Trio's design ensures that the fluid is not negatively affected by exposure to 
high temperatures during storage, this is not applicable to conventional designs. Especially 
those with single concentration bags. Although Gambro has phased out conventional PD 
bags in the Nordic countries, they are still commercially available in the European and Asian 
market  in addition to those offered by other  manufacturers.52 A study conducted in 2003 
discovered some peaks in temperature (~35°C) at different stages during the transportation 
chain of Gambro's conventional PD fluids at the time53. This is an indication of the risk of 
GDPs  occurring  in  single  and  double  concentration  PD fluid  design,  dependent  on  the 
amount of temperature control exerted by each manufacturer along the distribution chain.
51 Personal communication. Anders Wieslander. Gambro AB.
52 Personal communication. Malin Isacsson. PD Sales Manager. Gambro AB.
53 Nilsson L., Wallergård M. (2004) Distribution of Dialysis Fluid. Department of Design Sciences. Lund University. 
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4 Product system map
The main sources of input used in mapping Gambrosol Trio as part of a product system were 
the interviews with the members of the thesis steering group and with health professionals in 
direct contact with dialysis patients (dialysis unit at Universitetssjukhuset i Lund) and those in 
charge of supplying them with the items required for PD treatment (pharmacists working 
within the same health centres and delivery company in Lund and Malmö). 
See fig. 4-1 for an overview of the processes involved in the production,  use and disposal of 
Gambrosol Trio. The numbers in brackets in correspond to the locations where each process 
takes place as presented in fig. 4-2 (manufacturing and distribution)  and 4-3 (delivery and 
disposal).
Several assumptions have been made due to the sensitivity nature of information connected to the location and  
logistics involved with Gambro's supply chain. While these do not correspond to the actual location of suppliers  
in the manufacturing chain, they are required for the continuation of the exercise. A decision was made to  
place all suppliers in Europe as it was assumed better quality control would be possible within the Euro-zone  
compared to overseas suppliers. The results would naturally be significantly impacted if components are brought  
from outside Europe particularly in the case of transport by air. The assumptions are as follows:
• Glucose anhydrous manufactured in Sas-van-Gent, the Netherlands. This reflects the 
presence  of  a  large  glucose  producer.  Formerly  known  as  Cerestar  Pharma,  the 
company was bought by the US food group Cargill in 2002. Of the many Cerestar-
Cargill plants in Europe, Sas-van-Gent was identified as one of the main starch and 
glucose production points and was therefore selected for this exercise54. 
• PVC bag  and  Polypropylene  components  are  manufactured  in  Meyzieu,  southern 
France. Meyzieu hosts one of Gambro's facilities in France. Although this facility not 
responsible for the manufacturing of the bags themselves there were indications that 
Gambro's main supplier is located in southern France55. 
• Buffer, electrolytes, HCl are manufactured in Sondalo, northern Italy. Similar to PVC 
and  PP  components,  the  actual  supplier  was  not  available.  Since  none  of  the 
chemicals used in the solution are specialty substances it was deemed sufficient to use 
the location of one of Gambro's facilities as a place holder for this instance. 
• Packaging  (cardboard)  is  manufactured  in  Ovaro,  northeast  Italy.  This  refelcts  the 
location  of  one  of  Italy's  largest  cardboard  producers   located  in  relative  close 
proximity to Gambrosol Trio assembly point in Canosa Sannita, Italy.
As shown in fig. 4-1, each of the process steps has accompanying inputs in the  form of 
energy and material consumption (electricity and fuel use, materials for maintenance office 
operations). Likewise, each step produces outputs in the form of waste streams (air pollution, 
waste water and solid waste). 
To illustrate the previous point, we may consider that in general, glucose production requires 
starch  and  the  enzyme  glucoamylase  as  the  raw  materials.  Furthermore,  the  process  is 
conducted in batches at around 85ºC with durations of up to 72 hours.  After  a filtration 
54 http://www.foodnavigator.com/Financial-Industry/Cargill-VP-explains-reasons-behind-Cerestar-purchase  
    http://www.neth-water.nl/cms/page4.asp?active_page_id=112   
55 Personal communication. Theodor Sandström. Director of R&D. Materials and Chemistry Development. Gambro AB.
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stepis used to remove impurities created during enzymatic conversion, evaporation is used to 
concentrate the resulting glucose in order to ship it in solid form56. Waste streams include 
waste water from filtration, condensates and cleaning operations; solid waste from filtration 
and cleaning operations; air emissions as an indirect stream associated to the source of energy 
used throughout the production process.
Although a detailed description of all unit operations in each of Gambrosol Trio's process 
stages is  out  of  the  scope  of  this  thesis,  their  environmental  impacts  are  addressed  in  a 
simplified form in chapter 5 as part of this exercise.
For  a detailed breakdown of  the  components  in one  unit  of  Gambrosol  Trio please  see 
section 4.1.
56 London  South  Bank  University  (2008).  Production  of  glucose  syrup.  Available  online: 
http://www.lsbu.ac.uk/biology/enztech/glucose.html  [September 05, 2008]
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Figure 4-8: Gambrosol Trio System Map
24
LCA-based approach to environmental performance of Continuos Ambulatory Peritoneal Dialysis Fluids.
Figure 4-9: Gambrosol Trio system map.
[Glucose  production: the Netherlands, PVC & PP production: France. Packaging production: Italy.  
Product  Assembly:  Italy.  Distribution:  Lund,  Sweden.  Consumption:  Lund,  Malmö,  Ystad,  
Helsingborg, Hässleholm, Sweden] Source: Google Earth 2008.
4.1 Product components
Table 4-1 shows the components of one unit of Gambrosol Trio, the quantities used and 
their distances to production point in Italy and to distribution in Lund, Sweden. Distances 
between all the process sites were estimated based on land routes using a mapping and route 
planner freely available online57.
Table  2:  List  of  Gambrosol  Trio  components  with  distances  to  production  facility  and  to  Gambro  
Distribution Centre.
Component Name
[Origin]
Function Qt. 
[Kg]
Approx. 
Distance to 
Assembly
[Km]
Approx. 
Distance to 
Distribution
[Km)]
Gambrosol Trio 40
[Canosa Sannita, Italy]
Packaged Fluid for 
Continuous Ambulatory 
Peritoneal Dialysis.
2.49 NA 2079
57 Www.googleearth.com
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Component Name
[Origin]
Function Qt. 
[Kg]
Approx. 
Distance to 
Assembly
[Km]
Approx. 
Distance to 
Distribution
[Km)]
Plastic PVC-Phthalate 
bag (inc. cover bag)
Fluid Packaging 0.300
1013 NA
Polypropylene (PP) pins 
and caps
Breakable connecting pins 
between glucose 
compartments & 
Connection line caps.
3 x 0.000106
2 x 0.000996
1 x 0.001098
0.0022+
PVC-Phthalate 
connecting lines
Connection between fluid 
bag and catheter and 
catheter and drain bag. 
0.049++
Polypropylene clamps To secure bag and 
connecting lines during 
dialysis.
2 x 0.005 Kg
0.01+++
Glucose Osmotic agent (affects 
fluid removal during 
dialysis).
0.07800* 1596 NA
Sodium Lactate Buffer 0.00472
735 NA
Sodium Chloride Electrolyte 0.01614
Calcium Chloride Electrolyte 0.000209
Magnesium Chloride Electrolyte 0.000054
Hydrochloric Acid pH 0.044403 **
Cardboard Trio Packaging (1 box per 
4 units of Trio)
0.14*** 654 NA
Water Dialysis Vehicle 2.00 NA NA
+Based on rough estimates of volume of each piece and HDPE density of 0.96 g/cm3. ++ Based on rough 
estimate of volume of a 200 cm long PVC tube int Ø = 0.3mm and PVC density of 1.15 g/cm3. +++ Estimate  
based on size comparison versus breaking pins and line caps. *Equal to 3.9% w/w glucose concentration. ** 
Difference of Unit – Solution weight, exc. Hcl (2.350 – 3.394403 Kg) Although a rough approximation, it is 
considered sufficient in the absence of the exact concentration and amount of HCl required for pH at time of 
use. *** Assuming density of 900 g/m2 and box of 0.5x0.3x0.12m, 4 units packaged per box.
4.2 Product Manufacturing
As shown in figs. 4-2, production of Gambrosol Trio takes place at Biosol  S.p.A., one of 
Gambro suppliers, located in Canosa Sannita, Italy. Biosol receives the rest of the PD fluid 
components sent from suppliers (chemicals, packaging and tubing/clamps/caps)  that  then 
proceed to an assembly line  dedicated to mixing, filling and packaging the finished product. 
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From Biosol-Canosa, the finished product is sent by truck to Gambro's Distribution Centre 
(DC) for Europe, located in Lund, Sweden. This journey covers an approximate 1925 Km 
including a 154 Km section by ferry from Rostock, Germany to  Trelleborg, Sweden(see fig. 
4-3).  
Figure 4-10: From Manufacturing to Distribution Centre.
Source: Google Earth (2008).
4.3 Distribution
Gambro's  distribution  centre  in  Lund  controls  shipments  to  the  European  market  and 
therefore, only a fraction of the shipments managed at this DC are destined to the Swedish 
market. In the case of Sweden, Gambrosol Trio is sold and shipped to state-owned Apoteket 
AB  thus  ending  Gambro  AB's  traditional  product  chain  from  the  point  of  view  of 
commercial operations.
Apoteket  AB  is  the  entity  exclusively  responsible  for  the  commercialisation  of 
pharmaceuticals. In 2007, Apoteket reported net sales of approximately USD 6 billion, with 
operating  earnings close to USD 89 million and earnings after  taxes of  close to  USD 65 
million (Apoteket, 2008)58.
Apoteket  delivers  peritoneal  dialysis  products  to  patients  within  the  Swedish  health  care 
system. Due to the nature of renal disease, patients usually post orders to Apoteket either by 
telephone or email. In major Swedish urban centres, Apoteket maintains a dedicated store 
within city hospitals in addition to the regular stores that are available to the general public. It 
is in these hospital-pharmacies that PD fluids are stored prior to delivery to PD patients.  
58 Apoteket  AB  (2008).  Annual  Report  2007.  Available  online: 
http://www2.apoteket.se/Apoteket/om/Hem/default.htm [September 01, 2008]
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Five of these specialised Apoteket stores cover the needs of PD patients in Region Skåne 
(southern  Sweden).  They  are  located  inside  hospitals  (like  Lund  and  Malmö  University 
Hospitals) or in smaller health clinics where equipment and medical staff necessary for dialysis 
treatment are available. The location of the cities that host these stores are shown in figure 4-
3  and their distances from Gambro's Distribution Centre are shown in table 4-2.
Figure 4-11: Location of Apoteket stores that deliver PD products to patients in Skåne, Sweden.
Source: Google Earth (2008).
Table 3: Location of in-hospital Apoteket stores and distance to Gambro's Distribution Centre in Lund
Location Distance to Gambro Distribution 
Center
Hässleholm ~73 Km
Helsingborg ~56 Km
Malmö ~17 Km
Lund ~3 Km
Ystad ~71 Km
Of these  five  locations,  those  in  Lund  and Malmö were  approached  via  interviews with 
pharmacists in an attempt to establish the number of patients currently under PD treatment 
and  those  using  Gambrosol  Trio  as  well  as  those  using  similar  products.  Requests  for 
information (see appendix A) were made to the in-hospital Apotek stores in both cases in 
order to establish the figures stated above as well as wastage rates (due to returns and/or 
losses during routine handling) and safety inventory levels. 
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Of these  figures,  wastage rate was of particular importance due to  the  suspected  occurrence  of  
patients  changing their  glucose  concentration prescription while  still  having a stock  of  PD fluids in their  
houses59. In this case, that stock will usually not be used and must be discarded. 
The financial implications in terms of direct cost incurred by Apoteket stores when fluids are 
returned and have to be destroyed as well as the environmental impacts associated to wasted 
production were the reason why the scrapping rate at Apoteket was investigated.
Unfortunately, due to confidentiality limitations, not all of these figures were available.  Table 
4-3 summarises the data that was made available for this study.
CAPD patients in Sweden receive treatment at very low cost. They are required to pay a fee 
by the Swedish health care system of SEK 1,800 per year that covers the supply of PD fluids, 
accessories  and medication  that  may be  required.  The  cost  of  one  box  of  CAPD fluids, 
required for one day of treatment is estimated to be around SEK 80060
Patients usually place orders to cover their needs for one to two weeks worth of dialysis fluid. 
This is due to the space they have available at home to store the product. 
Table 4: Summary of data available from Apoteket stores in Malmö and Lund
Health 
Center
Number of 
CAPD 
Patients
Patients using 
Gambrosol Trio+
Number of PD bags 
sold to patients per 
producer
Wastage rate (returns, 
in-house/delivery 
losses)
Safety 
Inventory
Malmö ~45 ~ 60% NA (confidentiality) NA (not tracked) Minimum 1 
week
Lund 42 ~75% NA (confidentiality) NA (not tracked) Minimum 1 
week
4.4 Product Delivery
As for  the  final  stage  in  the  transportation  of  PD fluids,  Gambro's  Forwarding  Agency 
(Cullins Transporter AB) in Malmö was contacted to observe the delivery system that takes 
the product from the Apoteket to the patients. This Agency delivers all PD products and 
medication to the Apoteket customers. 
Although the delivery service is independent from Gambro (it  bills Region Skåne through 
Apoteket) it is coordinated from there and as such, all trips begin in Gambro AB's facilities in 
Lund, from there, the delivery truck goes to the in-hospital Apoteket in Malmö, it is loaded 
with the day's worth of PD products and medication and proceeds to deliver house by house. 
On the return trip the delivery truck also collects cardboard boxes, empty bags and full drain 
bags for those patients with limited access to waste collection (either because waste separation 
is not  implemented in their  housing units or because of their physical condition prevents 
them  from  doing  it  themselves)  and  returns  the  waste  to  Gambro  in  Lund  where  it  is 
aggregated to the facilities' similar waste production and eventually disposed of in bulk.
A 7.5 Ton diesel truck (see fig. 4-4) is used for deliveries and the delivery routes are optimised 
to some extent based on proximity of the patient's location and the estimated time that it 
59 This was corroborated during interviews with all external contacts. See Chapter 2 for the full list of interviewees.
60 Personal communication. Malin Isacsson. PD Sales Manager. Gambro AB.
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takes for one person to load, unload and deliver the fluids to the patient's storage. Delivery 
trips are made 4 times per week with six to 12 patients attended per day. 
Figure 4-12: 7.5 Ton diesel truck used for delivery of  
PD fluids in Malmö.
Truck load is variable on the orders placed for any given day and can range from an estimated 
5%  up to around 60% by volume (see fig 4-6 for observed final load). Table 4-4 summarises 
the observations made during one delivery trip to patients in and around Malmö.
Figure 4-13: Truck load to supply 8 PD patients in 
Malmö. 
(Approx. 30% load by weight and 20% by volume)
Table 5: Observations regarding product delivery.
Type of Vehicle used for delivery 7.5 ton Diesel truck
Type of fuel
Number of delivery trips 4 per week
Number of patients per trip 6 to 12
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Type of Vehicle used for delivery 7.5 ton Diesel truck
Truck load (by weight) 25 to 50%* 
(1044 Kg to 2088 Kg for 6 to 12 patients per trip, 
respectively).
Distance traveled 99 Km-patient / year**
*Based on 4.1 maximum load as per manufacturer specifications. **Estimate based on total mileage observed 
on board, for the period August 2006 – August 2007.
4.5 Use and disposal
In the case of patients in Malmö, patients can dispose of used dialysis and full drain bags as 
municipal waste by themselves. Full drain bags are emptied into the toilet and then both bags 
and other plastic components are placed into municipal waste bins. Separation of cardboard 
for recycling is dependent on cardboard bins close to their homes and this varies throughout 
the city. The option is provided by Gambro to take all waste materials back to one of its 
hemodialysis  manufacturing  units  in  Lund  where  it  is  incorporated  into  the  site's  waste 
stream. The alternatives for final disposal of bags and other plastic items are incineration or 
landfilling.
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5 Life Cycle Assessment-based approach: Why, how 
and how far?
This  chapter  makes  use  of  the  contextual  information  presented  in chapter  3,  the  insight  gained  by  the  
information presented in chapter 4 and a brief revision of Life Cycle Assessment as a viable tool that can 
answer the research questions stated in chapter 1. The chapter begins by looking at the context and product  
map to provide justification for the suitability of this approach, then describes the method itself, its components,  
advantages  and  disadvantages  and  explores  how  it  can  be  adapted  in  order  to  further  explore  the  
environmental performance of Gambro AB' dialysis product, given the resources and time constraints inherent  
to this thesis.
5.1 Why? A holistic approach
Although at first glance Gambro AB and their activities as a producer in the medical sector 
may be explained in the context of traditional business models like the one illustrated in fig. 
5-1, the reality is that the interactions of Gambro with both society and the environment go 
beyond acquisition of raw materials from suppliers and distribution of their products to their 
customers.
Figure 5-14: Traditional Business Model.
Source: Adapted from Anderson (1998)
A  more  holistic  approach  is  required  to  visualise  the  number  and  nature  of  the  actual 
interactions  of  an organisation  like Gambro.  The interface model proposed by Anderson 
(1998) is a good first step in this process. It shows how any organisation is linked to society 
and  the  environment  in  more  ways  than  simple  raw material  acquisition  and delivery  of 
finished goods. It punctuates how producers, through the use that their customers make of 
products, are also linked to environmental impacts due to disposal, use of alternative energy 
sources and technological improvements that may reduce material intensity, thus increasing 
their  organisation's  overall  environmental  performance.  Fig 5-2 summarises  the  expanded 
version of this interface model.
The relevant components of the expanded model as pertains to this study are the inclusion of 
indirect “customers” in Gambro's business model. That is, Gambro's products in general, and 
Gambrosol Trio in particular, do not end their relationship with the company as a producer 
at the time they are sold to the Apoteket which act as their direct customer, that is, the one 
engaged in the direct physical and monetary transaction. 
The  above  is  exemplified  by  the  fact  that  due  to  Gambrosol  Trio's  three-in-one  design 
(technological innovation) users that for whatever reason must change their fluid's glucose 
concentration while still having a stock of conventional fluids will not require additional fluids 
delivered to cover their new needs and will therefore not scrap their existing, now unusable 
fluid stock thus reducing  the  amount  of  “wasted” product  and with  that  the  amount  of 
materials that must be discharged as waste water (the fluid itself), landfilled and/or incinerated 
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(packaging material and the bag itself), avoid unnecessary raw material extraction and use as 
well as the impacts associated to the manufacturing of chemicals and assembly of the fluids 
themselves (see dashed lines in fig. 5-2).
Another important aspect of the model is the pressure exerted on the company's action by 
the stakeholders within the community, exemplified in this case by the recent and constant 
efforts of several pressure groups to phase-out the use of PVC and some of its associated 
materials in products like Gambrosol Trio that are used in the medical sector61.
All of the effects mentioned above are in this case driven by a technological innovation that 
did not have as its main goal the improvement of the product's environmental performance. 
However,  by  illustrating  the  indirect  effects  of  the  science  and  technology  behind  the 
product's  design  this  thesis  seeks  to  bring  attention  to  the  potential  of  using  similar 
development processes to actively seek environmental improvements whenever possible.
Figure 5-15: Expanded Interface business model.
Source: Adapted from Anderson (1998).
As can be inferred from fig. 5-3, the  actual environmental  behaviour of  Gambrosol  Trio 
depends on the actions not just of the company itself but of all of its suppliers upstream in 
the manufacturing chain as well as that of end-users beyond the company's direct customers.
The visualisation of an expanded business cycle serves as an adequate first step in addressing a 
product's environmental performance. However, in order to provide with more objective and 
goal oriented assessments, it is necessary to attempt a quantification of this performance all 
along the business cycle.
This  quantitative  “cradle-to-grave”  approach  is  one  of  the  basic  tenets  of  Life  Cycle 
Assessment and is covered in the next section.
61 USFDA (2002). See footnote 1.
HCWH (2008). See footnote 4
Medical Device Link (2006). See footnote 8.
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5.2 How?62
5.2.1 Life Cycle Thinking
Life  cycle  thinking  is conceptual  framework  that  takes on  ideas and process  visualisation 
similar to those presented using the interface model in the preceding section. It is one of the 
frameworks that were developed as a consequence of heightened environmental awareness 
which in turn, spurred the creation and use of concepts like sustainable development and the 
triple bottom line during the late 1990s and the early 2000s. 
The concepts like sustainable development and the triple bottom line stress the importance 
of  the  interactions  between  Social,  Economic  and  Environmental  factors  in  the  global 
production and consumption systems of today. Life cycle management is a particular type of 
business strategy that takes into account these concepts, combined with others like Corporate 
Social  Responsibility  in  order  to  develop  a  cohesive  and  systematic  way  to  achieve 
sustainability in the industrial sector and to communicate it to the relevant stakeholders. By 
doing  so,  competitive  advantage  may  be  established  by  the  inclusion  of  environmental 
concerns that drive eco-innovation and eco-design. 
The central concept behind life cycle thinking is the reduction of resource use and pollution 
throughout  the  life  cycle  stages of  a  given  product.  However,  product  design is  another 
crucial component that is meant to increase the extent to which a product can be reused, 
recycled or repaired.
The  framework  acknowledges  the  fact  that  environmental  impacts  must  begin  to  be 
quantified,  assessed  and  addressed  as  far  back  in  the  manufacturing  chain  as  possible. 
Likewise,  impacts  must be  tracked during the  use and disposal  phases that  are part  of  a 
product's lifetime. In order to do so, it makes use of specific tools, one of which is what is 
known as Life Cycle Assessment.
5.2.2 Life Cycle Assessment
The  are  several  definitions  of  what  LCA is  and  all  reflect  on  the  original  one  that  was 
developed by the International Standards Organisation in 1997 that classifies LCA as a “tool 
that allows to assess the potential environmental impacts from a product or system from raw 
material extraction to final disposal” (ISO, 1997 in Kørnøv et al. Eds., 2007).
The process of conducting an LCA can be summarised by the following steps (illustrated in 
fig. 5-3a and 5-4):
• Definition of Goal and Scope.
• Inventory Assessment.
• Life Cycle Impact Assessment (LCIA).
62 This section is based on the work presented in the following sources and draws extensively from them unless otherwise  
noted:
Baumann, H. Tillman, A. (2004). The Hitchhikers Guide to LCA. An orientation in life cycle assessment methodology 
and application. Ch. 1, 2. Studentlitteratur, Sweden.
--- (2007). Tools for Sustainable Development. Eds., Kørnøv L., Thrane M., Remmen A., Lund H. Ch. 11, 12. Aalborg 
Universitetsforlag.
USEPA  (2006).  Life  Cycle  Assessment:  principles  and  practice  [online].  Available  at: 
http://  www.epa.gov/NRMRL/lcaccess/pdfs/600r06060.pdf  [2008, August 10]
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• Interpretation.
Figure 5-16: LCA stages.
Source: USEPA (2006)
When defining the  goal and scope of  any given LCA several key factors  must be  clearly 
addressed.  For  example,  the  purpose  of  the  study may vary from the  need to  document 
processes  and  material  and  energy  flows within  the  organisation  or  it  may  be  part  of  a 
systematic marketing strategy focused on environmental concerns expressed by consumers. It 
is important to clearly define the target audience in order to provide adequate context and to 
prevent misuse of the results by non-intended audiences.  
The scope of the study is related to the determination of what is known as functional unit. 
The functional unit is a quantitative expression of the function a given product offers to the 
user. As such, it should accurately describe the function of the product, the duration of the 
provided function and qualitative aspects of the product.  The “number of coffee servings 
during a 10 day conference” would describe the function of ceramic and paper coffee cups 
during a well defined time horizon. Using servings instead of litres served reflects the fact that 
coffee does not only function as a stimulant but also as an element of social interaction.  
It's important to keep in mind that the question is how do the two products compare when 
their whole life cycle is taken into account. It might be the case that the water used during 
washing of  ceramic  cups  represents  considerably  smaller  impacts  than  the  use of  natural 
resources  (paper  production)  and  waste  disposal  (collection,  recycling,  land  filling  or 
incineration)  involved in  the  production  of  paper  cups when both  products  are  analysed 
identically from cradle to grave.
In this logic, the definition of a product's functional unit in LCA is very important because it 
leads to a reference flow. The reference flow is the basis for the calculations done in later 
stages of the method. Using the example above,  by using ceramic cups it  would stand to 
reason that a certain amount of water would be consumed during the conference for washing 
whereas paper cups would only involve water consumption during their manufacture. The 
reference flow will indicate that, among many others, “x” tons of raw materials, “y” tons of 
water and “z” MW of electricity are required for the manufacture of the required number of 
paper  cups.  Different  amounts  will  correspond  to  ceramic  cups  but  their  use  at  the 
conference will also involve the consumption of a given amount of water for cleaning and 
they will only require a fraction of resources when it comes to disposal.
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Another crucial part of this stage is the definition of system boundaries, that is, what will be 
the geographical (based on where the market for the product is), systematic (what processes 
and sub processes will be included) and temporal (validity of the study based on the status of 
technology and production practices and techniques) limits.
The goal and scope will also determine the nature of the study itself. It may mean that a single 
product is being internally assessed by an organisation or that a comparison will be made with 
competing  products  that  have  similar  functions  and  are  available  in  the  market.  Single-
product LCA allows for a first screening of life-cycle stages of importance and can facilitate 
the selection of for example, alternative materials, suppliers or manufacturing lines.
The  inventory  analysis  stage  consists  of  the  description  of  processes  and  collection  of 
quantitative and qualitative data on the inputs and outputs throughout the products life cycle 
(see  fig  5-3).  This  means  inputs  and  outputs  must  be  defined  for  raw materials,  energy 
carriers,  the  product  itself  and  solid  waste  and  water  and  air  emissions.  An  important 
consideration during this stage is that  of allocation.  Allocation occurs when a component 
used in the product's life cycle is also used in different production systems.  An example is in 
shared transportation of bulky materials. If two or more different materials are transported in 
the same truck, the air pollution emitted will be distributed among the transported materials 
as it is volume that determines truck loading. This guarantees that the material of interest will 
only  be  assigned  its  relative  emissions  and  not  those  of  other  materials  that  share  the 
transport trip.
Figure 5-17: LCA fundamental  components: Boundaries, Processes,  
Input and outputs. 
Source: USEPA (2006)
Stage  3 or  LCIA uses the  inventory  developed in  the  preceding  stage  in  order  to  assess 
potential  environmental  impacts.  Causal  links  have  been  established  between  inputs  and 
outputs (e.g., emitted CO2 and NO2 due to fuel combustion, discharged P04) and effects such 
as global warming, eutrophication or acidification.  All the inputs and outputs are categorised 
and aggregated based on their causal relation to specific environmental impacts as mentioned 
above. In this way, the total emissions of global warming agents are expressed as a single 
figure like number of Kg CO2 equivalents or SO2 equivalents in the case of acidification. 
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Optional steps in the LCIA stage are normalisation and weighting. Normalisation refers to 
the  expression  of  figures  such  as  Kg.  CO2 equivalents  in  terms  of  something  that  the 
audience can more easily relate to. For example, the annual contribution to global warming of 
an average individual can be used as a reference.  In this way, “x” product can be said to 
contribute to this average individual's global warming effect by 0.5%. This is easier for the 
audience to understand than telling it that the product has a total effect equal to the emission 
of “x” number of Kg. CO2 equivalents.
Weighting is a way to assign priorities to the different environmental impacts associated with 
a  product's  life  cycle  by  means  of  weighting  factors.  Weighting  may  be  made  based  on 
regulatory  targets  (such  as governmental  imposed emission  reductions  of  SO2)  or  on  the 
levels of available non-renewable resources. Monetary weighting, based on willingness to pay 
can also be used. Finally, groups of experts can be approached in what is known as panel 
weighting to discuss and reach consensus on the priority of the impact categories (e.g., the 
effects of acidification may be deemed more important that global warming in a sensitive or 
relatively isolated marine micro-region).
Finally,  during  the  interpretation  stage,  key  inventory  and  impact  assessment  results  are 
presented in order to identify the salient environmental issues concerning the product under 
study. A case must be made for the sensitivity (how the results are affected by variations in 
the  inventory  for  example),  completeness  (whether  all  available  information  has  been 
included or not) and consistency (if the methods used throughout the study follow a coherent 
and logical pattern)  of the LCA as a whole. In the case of recommendations, perhaps the 
most crucial consideration is to explicitly address the assumptions that form the basis for any 
recommendations as per the results of the Assessment.
5.2.3 How far? Screening LCA as a compromise
The  execution  of  a  full  Life  Cycle  Assessment  would  involve  the  development  of  a  full 
inventory database for all the process stages involved in the manufacturing, distribution, use 
and  disposal  of  Gambrosol  Trio  as  presented  in  chapter  4,  followed  by  a  full  impact 
assessment of all identified input and output streams. Impacts would then be grouped into 
categories and a final score would have to be assigned to the product as a whole based on the 
selected weighting criteria. The same procedure would then have to be followed for a similar 
product delivering the same function in order to be able to assess Trio's performance against 
a benchmark. An endeavor of this magnitude is out of scope for this thesis so a compromise 
was sought that would be able to make use of the general method as developed for LCA but 
that could be limited and usable to pursue further insight into the product's environmental 
performance.
Shortly after the formalisation of LCA as a tool for decision making, analysts discovered the 
risk associated with attempting to use unreasonable amounts and quality levels of data in their 
assessment as an over-extended attempt can hinder the decision making process itself, both 
due to the time it takes to complete it and the amount of financial resources required. As a 
result, may options have been explored to simplify its application to reasonable levels. Still 
within the scope of the original method, analysts have often tried to simplify, or 'streamline' 
the method by reducing the amount and difficulty involved in data collection by reduction of 
boundaries,  using  qualitative  and  quantitative  data,  limiting  impact  categories  and  impact 
assessment (Curren, 1996).
The two basic alternatives to full-scale life cycle Assessment are known as conceptual and 
screening LCA. Conceptual LCA is a strictly qualitative approach and as such can only be 
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considered  during  the  very  early  stages of  any serious  evaluation  effort.  It  requires  basic 
knowledge of the product system and its interactions with the environment. 
Screening  LCA is  based  on  the  traditional  LCA method  but  it  allows  for  simplification 
beyond  streamlining  as  described  above  by  allowing  qualitative  or  surrogate  data  (e.g., 
estimates and equivalent data available in databases) or by focusing only on one or a few data 
and impact categories (e.g., screening only for energy use and addressing global warming).
It is important to note that, according to International Standard that sets the guidelines for 
LCA,  neither  conceptual  nor  screening  LCAs should be  considered  equal to  full LCA in 
terms of their implementation and results. Instead, they are approaches that use and adapt 
LCA-based technique.
The main criteria encountered in the literature (Thrane, Schmidt in Thrane et al. 2007) that 
relates to the use of either conceptual, screening or full approaches basically revolves around 
the purpose behind the use of LCA technique itself.
When the purpose is to evaluate environmental policies at company-wide levels or to develop 
new guidelines for product developments then the full approach is suggested as the results of 
the exercise may have a long-term impact not only on the organisation itself but potentially 
on the whole production-consumption system as well. The same holds true when the results 
of the assessment will be communicated to stakeholders outside of the organisation's direct 
area  of  influence  since  this  requires  a  greater  level  of  attention  to  accuracy, 
comprehensiveness and transparency.
If the purpose is internal identification of areas of concern in terms of environmental impacts 
(i.e,  stages along the  product  chain where  impacts  might  be  critical)  or  as a documented 
response to stakeholder pressure then a combination of streamlined LCA and conceptual or 
screening LCA might be used instead.
As  part  of  this  thesis,  the  screening  LCA approach  was selected  based on  the  following 
reasons:
• The purpose is to gain further insight into whether or not the product's packaging 
design, developed exclusively to increase its functional performance, could also result 
in better environmental performance when compared to similar products.
• Gambro is now facing increasing pressure from stakeholders when it comes to the 
use  of  PVC  and  phthalates  in  their  products.  Although  there  is  no  conclusive 
evidence  of  the  negative effects  of  either  chemical  on  human health it  has been 
identified as a potentially toxic compound for other species63.
• Although the health care sector has experienced some success in phasing out PVC 
from certain products, alternative materials are not yet available at an equal cost when 
it comes to peritoneal dialysis bags. Thus a decision to switch to a different material 
can not be based on costing alone64.
• Although the organisation has an environmental management system based on the 
ISO-14001 standard  for  their  day  to  day  operations,  for  part  of  the  organisation 
(represented  by  the  steering group as defined in chapter  2)  is actively seeking for 
63 See chapter 1
64 Ibid
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alternatives to extend their environmental efforts beyond their traditional EMS. As 
such, the purpose of this exercise is to use a screening approach as an introduction to 
the full LCA approach.
5.2.4 Applied Screening LCA for Gambrosol Trio
This section is based on the core components  of the full LCA approach as presented in 
section 5.3 and it includes the limitations that were encountered for each of them. 
Goals.
The goals of this exercise reflect the purpose of the thesis as a whole as described both in 
chapter 1 and in the preceding section  as part of LCA methodology. They are:
• To gain further insight into the environmental performance of a three compartment 
glucose PDF (Trio).
• To explore the implications of 3-in-1 design in the distribution and use phase of the 
product.
• To introduce/reinforce knowledge and approaches based on LCA thinking within the 
organisation.
 Functional unit and reference flow
The functional unit is important whenever quantitative insight is to be pursued as it forms the 
basis for calculations involving input and output inventories. 
The first step to define the functional unit of Gambrosol Trio is to consider its function. This 
is important due to the importance that is placed in the product's packaging design as the 
source of potential environmental benefits.
Strictly speaking, a CAPD patient is only interested in the fluid contained in the package as a 
means to substitute renal function. In that sense, they are buying the fluid not the bag itself. 
Thus, the function of the product can be summarised as follows:
“To substitute a patient's renal function by means of a peritoneum-based fluid 
exchange-”
The product's bag comes into play when referring to the quality of the provided function. As 
was described in chapter 3, Gambrosol Trio reduces the amount of Glucose Degradation 
Products present in the dialysis fluid and there are indications that this can lead to preserving 
the  peritoneum  for  longer  periods  when  compared  with  fluids  that  contain  higher 
concentrations of GDPs.
The duration of PD as a treatment option depends on many variables. The extent of renal 
failure, infection,  associated illnesses,  transplant  availability  and death can all influence the 
duration of treatment. Although there have been cases of patients being on CAPD for over 5 
years65, some studies have shown that there is a marked increase in risk of death after the 
second year of CAPD therapy66.  No definitive data on treatment  duration was found for 
65 Personal communication. Lena Krutzen. Dialysis Unit. Universitetssjukhuset i Lund 
66 http://www.medscape.com/viewarticle/538757  
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CAPD but 2 years was considered as a reasonable approximation based on the information 
available and the estimates provided by the steering group.
As for qualitative aspects, a patient's choice of Gambrosol Trio over a similar product appears 
to be related to the ease of use of the product, both for training of medical staff at health 
centres and for patients at home67. This is due to the fact that patients have to “break” one or 
two of the plastic pins within the bag in order to get the required glucose concentration in 
every exchange. A competing product uses a different design that is actively marketed as a 
simpler  alternative to  Gambrosol  Trio68.  Finally,  a degree  of  hand strength  is required to 
break the pins and elderly patients might encounter difficulties with Trio's design. 
Taking  into  account  the  factors  mentioned  above,  the  proposed  functional  unit  for 
Gambrosol Trio as a CAPD fluid is:
“Number of PD exchanges during the course of an average PD patient's treatment”
CAPD involves 4 exchanges per  day;  using 2 years as the  duration  of  an average CAPD 
patient means 2192 exchanges will be conducted during that period of time. At 2 litres per 
exchange, that means that 5824 litres of CAPD fluid be required by the average treatment 
patient.  Although the  number of litres serves well to represent  the reference flow of this 
product,  it  was  decided  to  use  the  number  of  exchanges  instead  since  all  the  product 
components are referred to in terms of a single 2-L bag.
Therefore,  for  this  exercise,  the  reference  flow  is  equal  to  2192  exchanges  using 
packaged CAPD fluid.
Boundaries
The first set of boundaries are those that deal with the product system itself.  During the 
initial rounds of discussion with the steering group at Gambro AB it was suggested to focus 
the  work  on  the  distribution  stage  in  the  product  system  with  especial  regard  to 
transportation during distribution and delivery. However, the author considered it important 
to touch on the production and manufacturing of components as well, especially because of 
the  attention  that  is  being  currently  placed  on  the  use  of  PVC and phthalates  (as  PVC 
plasticisers) by different stakeholders in the health care sector (see chapter 1).
The initial focus on distribution and delivery was due to an initial assumption that Apoteket 
stores would have to have all three concentration solutions (for products other than Trio) 
available for the total number of CAPD patients in the event of them switching prescription 
on a contingency basis. If this were the case, it would be reasonable to think that the use of 
Gambrosol Trio would have significant advantages due to reduced manufacturing, storage, 
transport  and wastage  of  unused bags.  However,  during  interviews with  pharmacists  and 
health care professionals it was observed that this was reckoned to be a limited occurrence. 
Changes in glucose concentration appear to be a more or less regulated instance, mediated by 
continuous  monitoring  of  patients'  renal  functions  and  liquid  retention.  Patients  do  not 
necessarily have to have all three concentrations available at home in the sense that a different 
concentration is not required on a day-to-day basis. This means that patients usually store a 
single  concentration  for  extended  periods  of  time  and  only  if  their  concentration  needs 
    http://www.nature.com/ki/journal/v73/n108s/abs/5002606a.html   
67 Personal communication. Malin Isaacson. PD Sales manafer. Gambro AB. 
68 Product  information  on  Fresenius  Medical  Care's  Stay  Safe  system.  Available  online:  http://www.fmc-
ag.com/internet/fmc/fmcag/neu/fmcpub.nsf/Content/Continuous_ambulatory_PD  
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change they will order new product even if they still have bags with the previously required 
concentration. In this case bags no longer required are returned to Apoteket where they must 
be destroyed as it can not re-enter the market once it has been delivered69.
These observations resulted in the inclusion of component production and manufacturing as 
illustrated in fig. 4-1.
The next set of boundaries is that related to the geographical delimitation of the study. This 
set of boundaries is particularly important when conducting full-scale LCA as it is related to 
the spatial extension of environmental impacts. 
In the  case of  Gambrosol  Trio,  although manufacturing of  components  and the  product 
itself  is  located  over  many  European  borders,  the  geographical  focus  of  the  study is  on 
Region Skåne, southern Sweden. The reason for this is two-fold. Gambro is head quartered in 
Lund, Sweden and a good deal of research, development and takes place at this location. In 
this sense, the author hopes that the results of efforts within the environmental field such as 
this study will have a greater chance of disseminating to the rest of the organisation and its 
manufacturing sites and suppliers. Gambrosol Trio is sold in Europe and Asia under different 
arrangements depending on the health care system in each country; the inclusion of such a 
widespread use-phase base was deemed to be out of scope for the purposes of this study. 
The last set of boundaries addressed in this thesis is that related to a time-horizon. According 
to  the  steering  group,  production  of  Gambrosol  Trio  has  not  experimented  major 
technological  modifications  since  it  was  first  initiated  in  the  early  part  of  this  decade. 
Likewise, the steady increase in the number of individuals that will require CAPD as a form of 
renal  treatment  is  not  expected  to  drive  major  modifications  in  the  system.  Pressure  to 
substitute PVC and/or phthalates seems to be the main potential driver for change in the 
near  future.  However,  change ofmaterials in this  regard is not  expected  to  occur  at  least 
within the next five years. This period is therefore considered as a reasonable time boundary 
for this exercise.
Inventory Analysis and Impact assessment
Inventory analysis and impact assessment are based on the components presented in table 4-
1. In a strict application of full-scale LCA, every material and energy input and output that 
would result from the production and transport  of each of those items would have to be 
quantified to create the product's inventory. For example, inputs and outputs associated to 
the production of vegetable matter as a precursor of glucose production would have to be 
included and the same would apply to the production of each of the chemicals used in Trio's 
formulation.
This list of materials (considering energy converted to mass as per the fuel combusted to 
generate it) would then have to be characterised and aggregated according to a predefined list 
of environmental impact categories as was described in section 5.2.2 
Several methods have been developed to simplify the use of LCA-technique when it comes 
to impact assessment as the subsequent step after inventory  analysis.  In general,  some of 
these methods are intended to provide a single score or index that conveys the environmental 
burden associated to a given process unit. It is important to note that simplicity here means 
that a considerable number of scores for a variety of processes are currently available and can 
be  applied  directly  to  the  input/output  inventory.  However,  each  score  contains  the 
69 Personal communication. Katalin Kiss. Pharmacist, Universitetssjukhuset i Lund  in-house Apoteket. 
Personal communication. Lena Kempf. Head Pharmacist for dialysis. Universitetssjukhuset i Malmö  in-house Apoteket. 
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evaluation of the environmental impact of each process based on a natural science approach 
that  is complemented by a set of  predefined environmental impact categories and impact 
weighting criteria. Simplification then, in strict terms, comes from the criteria, assumptions 
and estimated data used by each method to provide each environmental index or score.
One of these methods, “Ecoindicator 99 (Eco99)” was selected for use in this exercise due to 
the general availability of usable scores for the processes that form part of Gambrosol Trio's 
product system. Originally commissioned by the  Netherland's  Ministry of Housing Spatial 
Planning and the Environment it is one of a series of LCIA methods recommended in the 
literature for screening LCA ( Kørnøv et al, eds. 2007).
This method was developed as a complementary tool in the evaluation of environmentally 
preferable  designs.  As  such,  it  can  only  be  used  to  initiate  the  exploration  of  life  cycle 
concerns and considerations and cannot be used as a marketing tool or as a means to prove 
or disprove claims to the general public. However, the method was developed as a tool to 
facilitate decision making early on in the design process70.  
Eco99 scores are available for material production,  process operations,  transportation and 
disposal. They are built around three impact categories: human health, ecosystem quality and 
resource  depletion.  The  method  originally  used  a  panel  approach  (a  group  of  365 LCA 
practitioners in Switzerland) to assign priorities to the impact categories mentioned above71. 
Throughout the analysis, a higher ecopoint count means higer environmental impacts. The 
calculations log is included as a spreadsheet file in Appendix 2. The original document used as 
the basis for the application of this method is included in Appendix 3. Also included is the 
Methodology Annex of the method that contains all the background information originally 
used by the developers of Ecoindicator '99 to arrive at the ecoscores per material requirement 
that were used in this exercise. 
Material and transportation requirements
Table 5-1 shows the total amount of materials required to deliver 2192 exchanges during an 
average  CAPD patient's  treatment  and  the  distances  they  are  transported  as  part  of  the 
product's system. This material amounts will be the basis for the use of Ecoindicator 99 to 
generate  Eco99  scores  for  transportation,  component  manufacturing  and  processing, 
manufacturing of the product itself and disposal.
Table 6: Total material requirements per Reference Flow
70 Ministry of Housing, Spatial Planning and the Environment (2000). Eco-indicator 99 Manual for Designers. A damage 
oriented  method  for  Life  Cycle  Impact  Assessment.  Available  online:  http://www.pre.nl/eco-indicator99/ei99-
reports.htm [September 01, 2008]
71 Idem.
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Ton * Km
2.050000 5969.6000 Italy-Lund-Apoteket-Patients
2321.1 13856.04
0.300000 873.6000 France-Italy
1013 884.96
0.049000 142.6880 France-Italy
1015 144.83
0.002200 6.4064 France-Italy
1014 6.5
Polypropylene clamps 0.010000 29.1200 France-Italy 1016 29.59
Glucose 0.078000 227.1360 Netherlands-Italy 1596 362.51
Sodium Lactate 0.004720 13.7446 Italy (Sondalo-Canosa Sannita) 735 10.1
Sodium Chloride 0.016140 46.9997 Italy (Sondalo-Canosa Sannita) 736 34.59
Calcium Chloride 0.000209 0.6086 Italy (Sondalo-Canosa Sannita) 737 0.45
Magnesium Chloride 0.000054 0.1572 Italy (Sondalo-Canosa Sannita) 738 0.12
Hydrochloric Acid 0.044403 129.3015 Italy (Sondalo-Canosa Sannita) 739 95.55
W ater 2.000000 5824.0000 NA 0 0
Cardboard 0.140000 407.6800 Italy (Ovaro-Canosa Sannita) 654 266.62
M ass 
requirements 
KG/unit
Total  required 
per RF [Kg/unit 
x  RF]
Considerations – 
Transportation
Distances 
[Km]
Gambrosol Trio 40 2L PDF 
bag
Plastic PVC-Phthalate bag 
(inc. cover bag)
PVC-Phthalate connecting 
lines
Polypropylene (PP) pins 
and caps
Ecopoints in Gambrosol Trio's life cycle
The following series of tables show the results obtained when applying ecoindicators to the 
material and transportation  requirements in table 5-1. Table 5-2 shows the scores for the 
production and processing of the product's components. Tables 5-3 and 5-4 show the scores 
for transportation and disposal, respectively.
Ecoscores  are  adimensional  in  principle  as  they  reflect  all  the  considerations  for  impact 
assessment that are inherent to the method. However, they were developed in such a way 
that 1 ecopoint is roughly equivalent to one thousandth of the environmental burden that 
corresponds to the average European resident72.
Table 7: Ecopoint score for production and processing of Gambrosol Trio's component
PRODUCTION AND PROCESSING
Components Ecopoints
873.6000 248.1024
PVC-Phthalate connecting lines 142.6880 40.5234
Polypropylene (PP) pins 6.4064 2.2486
 Polypropylene clamps 29.1200 10.2211
Glucose 227.1360 22.4865
Sodium Lactate 13.7446 1.3607
Sodium Chloride 46.9997 0.3102
Calcium Chloride 0.6086 0.0323
Magnesium Chloride 0.1572 0.0083
Hydrochloric Acid 129.3015 5.0428
W ater 5824.0000 1.5142
Cardboard 407.6800 28.1299
Total 7701.4421 359.98
Total requirement 
[Kg]
Plastic PVC-Phthalate bag (inc. 
cover bag)
72 Ibid.
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It is important to note that although Ecoindicator 99 has values for some of the components 
(e.g.,  Sodium Chloride and Chlorhydric Acid) others are absent and reasonable subsititute 
ecoindicators had to be used. For example, there is no indicator for the production of glucose 
and the entry for “organic chemicals, average” was used instead.
This is particularly important in the case of water processing. Gambrosol Trio as well as other 
dialysis fluids must use water of a high purity level, assumed to be achieved by ultrafiltration. 
Ecoindicator 99 has indicators for production of decarbonised and demineralised water. The 
latter with a score higher by one order of magnitude. The score for demineralised water was 
used after raising it one order of magnitude further. This attempts to reflect and include the 
use of ultrafiltration in the case of the finished product.
Likewise, there is no score that can be used for operations similar to those that take place at 
Gambro's facility in Canosa Sannita (Italy) where all the components are mixed, filled in to 
the  dialysis bags and packaged for  distribution.  In  this  case a simplification  was made by 
attempting to estimate an energy consumption rate to represent these operations. To do this, 
energy consumption values for packaged milk production were used in order to reflect similar 
quality and hygiene requirements. A value of 1.66 MJ / Kg of packaged Gambrosol Trio was 
used73. 
As for disposal, an assumption was made that all the waste enters the municipal waste stream 
except for cardboard which can be recycled. Plastic items were assigned a 50-50% destination 
in either landfills or incineration. Negative values in this instance correspond to the avoidance 
of manufacturing of new products due to recycling and electricity or thermal power generated 
due to incineration. Furthermore, it was assumed that 90% of the solid waste stream ends up 
in incinerators and only 10% goes to landfills. 
Table 8: Ecopoint score for transportation, distribution and delivery of Gambrosol Trio
73 Foster,  C., Green, K., Bleda, M. Dewick,  P., Evans, B., Flynn A., Mylan, J.  (2006).  Environmental Impacts of Food 
Production  and Consumption:  A  report  to  the  Department  for  Environment,  Food and Rural  Affairs.  Manchester 
Business  School.  Defra,  London.  Available  online: 
www.defra.gov.uk/science/Project_Data/DocumentLibrary/EV02007/EV02007_4601_FRP.pdf  [September 10, 2008]
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Table 9: Ecopoint score for waste disposal.
PVC Items (bag and lines) 1016.29 20.22
35.53 -0.17
Cardboard 407.68 -3.38
Total 1459.49 16.67
Waste 
produced 
[Kg]
Ecopoints [50% 
incineration, 50% 
landfilling, 100% 
cardboard recycling]
Polypropylene Items (pins, caps 
and clamps)
Figure 5-5 shows the ecoscores for Gambrosol Trio from production and processing of its 
components to the disposal of the waste generated after its use. Fig. 5-6 shows the difference 
in impacts coming from a theoretical switch from truck-based transport to rail. As per the 
Ecoindicator '99, this assumes a mix of 80% electrical and 20% diesel-based rail.
Figure 5-18: Ecopoint score throughout Gambrosol Trio's life cycle
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Figure 5-19: Ecopoint score throughout Gambrosol Trio's life cycle (rail).
Figs. 5-5 ad 5-6 give indication as to how the environmental impacts of Gambrosol Trio are 
spread all along its life cycle. As was stated above, there is uncertainty in this results in terms 
of the true scale of the impacts associated to the production of Trio itself. 
In order to gain further insight into the potential consequences of a material shift from PVC 
and phtalates to the use of alternative plastics, ecoscores were recalculated based on company 
information  about  potential  substitutes.  The  assumption  was  made  that  the  dialysis  bag, 
connecting lines and other plastic items would be made of:
• Polypropylene.
• A  combination  of  Polyethylene  (bag  and  components)  and  Polypropylene 
(connecting lines)
Theoretical ecoscores  using these  two combinations  are presented in figures 5-6 and 5-7, 
respectively. Figure 5-8 shows a comparison of the total ecoscores for Trio as it is now and 
with alternative materials.
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Figure 5-20: Ecoscores after substitution of PVC with Polypropylene
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Figure 5-21: Ecoscores after substitution of PVC with PET-PP
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Figure 5-22: Ecoscore for bag production depending on material alternative.
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Finally, the scrapping rate was included in the analysis in order to gain insight into the extent 
of the advantage of Trio's design compared to one and two-in-one concentration designs.
Due to the fact that data was not available for products from competing producers, ecoscores 
were calculated based on the material and energy requirements as presented in Table 5-2 and 
adding  an  extra  10 percent.  This  is  meant  to  represent  that  patients  using  a  competing 
product  would  scrap  up  to  10%  of  their  supplies  due  to  changes  in  prescription. 
Unfortunately, data on actual scrapping at Apoteket was not available as it is not tracked by 
the  stores  that  were  approached during this  study.  The  figure also aims to  represent  the 
infrequent  nature  of  the  prescription  changes  as  was  observed  during  the  interviewieng 
period.
It is important to note that, all else equal, the fact that Ecoindicator 99 uses mass as the base 
for its indicators means that it was possible to add the scrapping rate directly to the ordinary 
Ecoscore for Trio. This means changes in prescription would only stimulate production of 
one bag of the demanded new concentration so that the patients needs as expressed in the 
functional unit can still be covered during treatment. 
Using a 10% scrapping rate resulted in an increase in the total ecoscore for Gambrosol Trio 
from 575 to 633.
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6 Findings and conclusions
The screening LCA approach used in this study shows that the majority of the environmental 
burden associated with the production and use of Gambrosol Trio as a fluid for Continuous 
Ambulatory  Peritoneal  Dialysis  appear  to  be  concentrated  in  the  production  stage  of  its 
different  components  and of  these,  the  production  and processing  of  the  bag and other 
plastic items are the greater contributors.
These findings cannot be regarded as conclusive due to the limitations of the approach itself 
and to the assumptions used during the Assessment. Of particular importance is the lack of 
indicators  for  the  manufacturing of  the  finished product  at Gambro's  facility  in Italy.  An 
estimate of energy consumption was the criteria used to assign a score, disregarding air and 
water borne pollution.
In spite of the limitations, the results shed some light into the performance of the product 
througout its  life cycle,  and were  particularly useful in bringing attention  to the  fact  that, 
considering the  limitations  of  this  exercise,   the  product  design does not  appear  to have 
significant environmental effects in the distribution, delivery and use phase.
The main reasons for this were the observations that pointed to the fact that CAPD patients 
do not seem to change their glucose concentration prescription on a contingency basis. The 
prescription appears to depend on continuous monitoring of the patient's renal function and 
changes do not happen suddenly. Furthermore, patients usually place orders for CAPD fluids 
in intervals of 1 to 2 weeks, depending on space available for storage and the Apoteket uses 
these orders as the basis for their inventory stock. It is reasonable to conclude from these 
observations that orders placed from Apoteket stores to manufacturers of CAPD solutions 
also follow this pattern and therefore, production of all three concentrations for every patient 
does not take place to a larger extent.
It is important to note that this exercise does not compare Trio's performance to its direct 
competitors.  Therefore,  it  is  not  possible  to  clearly  distinguish  the  advantages  of  Trio 
transport  versus that  of  its  competitors  even  though  it  is  reasonable  to  expect  that  the 
reduced volume of Trio would mean lesser impacts in distributer-to-patient transport. As a 
counter-point, a next step would be the assessment of the impacts related to wasted glucose 
occurring  with  Trio (when  using lower  concentrations)  use as compared  to  100% use of 
glucose in other designs.
There were some indications of wasted fluid but unfortunately they are not formally tracked 
by the Apoteket stores that were approached during this study (see Appendix 1). Ecoscores 
were calculated using an assumed scrapping rate of 10%. Results show that the scrapping rate 
has  an  additive  character  in  its  effect  on  the  products'  ecoscore.  Although  no  data  was 
available to calculate ecoscores for competing products, the result provides some insight into 
the extent of the environmental advantage of Trio with regards to scrapping.
A measure of insight was also gained into the decision that the company is currently facing on 
whether or not to substitute PVC and phtalates as the bag and other components material of 
choice. The results show that in terms of material production, processing and final disposal, 
alternative materials such as Polypropylene and Polyethylene do not necessarily improve the 
environmental performance of the product.
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It  is  important  to  note  that  the  comparison  of  plastics  use was done  assuming an equal 
amount of material is required to produce all plastic components. This does not take into 
account any reductions that may be achieved due to differences in PP and PET density.
The use of recycled polypropylene and polyethylene in plastic manufacturing would lower the 
environmental burden of their production stages. Unfortunately this would present the risk of 
having a number of unknown additives in the recycled mix, a situation that would not be 
acceptable in the production of medical devices due to the same toxicity concerns that drive 
the issue of PVC replacement.
Insight into the environmental characteristics of the materials for the dialysis bag is important 
since so far the debate has revolved around the potential toxicity to human health of PVC 
and phtalates.  This  type  of  exercise  adds  a  new dimension  to  the  debate  by  including  a 
broader  look  at  the  environmental  implications  that  come  with  choice  of  materials. 
Unfortunately, no data was found as to the effects of phtalates released into the environment, 
either as a result of leakages in landfills or incomplete combustion in incinerators.
The results also mark the need to open and maintain a constant dialogue with suppliers, both 
to  maintain  an  up  to  date  and  easily  accessible  inventory  database  as  well  as  to  track 
opportunities  for  actions  such  as  material  replacement  or  eco-efficiency  improvement 
programs.
50
LCA-based approach to environmental performance of Continuos Ambulatory Peritoneal Dialysis Fluids.
7 Recommendations
This  thesis  was  conducted  as  a  first  approach  to  Gambrosol  Trio's  environmental 
performance  and  cannot  provide  conclusive  evidence  that  may  be  used  for  marketing 
purposes or for official communication with stakeholders. However, it does provide insight 
into the environmental performance of the product throughout its lifecycle and is intended to 
present Life Cycle Approaches as a tool that, if applied to the full extent and rigor of the 
method,  can  provide  more  conclusive  findings  into  the  true  measure  of  the  product 
performance.
A full-scale Life Cycle Assessment is therefore recommended should the organisation decide 
to pursue the use of this tool to complement the decision making process in order to include 
environmental  criteria,  especially  during  the  research  and development  stages  of  product 
development and in particular as a central decision making tool in the topic of PVC and/or 
phthalate substitution.
At the time of writing, the organisation's environmental management system (EMS), based 
on the ISO 14001 standard, was being re-structured. This can be a crucial opportunity to 
include  comprehensive  approaches  like  life  cycle  assessment  to  become  one  of  the 
instruments with which to execute the organisations environmental policy. In turn, due to the 
hierarchy  of  this  policy,  it  would  be  expected  that  its  effect  would  trickle  down  to  the 
research and development and production areas of the company.
The complexity and resource intensity of full-scale assessments run the risk of transforming 
the tool into a barrier for the decision making process they are meant to assist. To counter 
this, it is strongly recommended to continue the practice of creating “steering” groups as was 
the case for the duration of this study. The interaction of relevant players from different areas 
within the organisation can greatly facilitate exercises of this nature.
Should these approaches be used in the future, it is recommended to also include production 
and  logistics  managers  located  both  at  home  and  abroad  as  they  can  greatly  assist  in 
complementing the information required for analysis. 
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Appendix 1
Request for information, Lund:
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Response, Lund:
The same request was made in Malmö. A response from the Apoteket there was delivered in 
person by Lena Kempf,  Head Pharmacist  for  dialysis,  and was virtually  identical to  that 
received from Lund.
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Appendix 2
The log with the calculations performed for the Assessment  is available as an electronic 
spreadsheet.
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Appendix 3
Ecoindicator '99 Manual for Designers.
Ecoindicator '99 Methodology Annex.
See in references: 
Ministry of Housing, Spatial Planning and the Environment (2000). Eco-indicator 99 Manual 
for  Designers.  A damage oriented  method  for  Life  Cycle  Impact  Assessment.  Available 
online: http://www.pre.nl/eco-indicator99/ei99-reports.htm [September 01, 2008].
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